1. Developmental Biology

The novel ciliogenesis regulator DYRK2 governs Hedgehog signaling during mouse embryogenesis

  1. Saishu Yoshida
  2. Katsuhiko Aoki
  3. Ken Fujiwara
  4. Takashi Nakakura
  5. Akira Kawamura
  6. Kohji Yamada
  7. Masaya Ono
  8. Satomi Yogosawa
  9. Kiyotsugu Yoshida  Is a corresponding author
  1. Department of Biochemistry, The Jikei University School of Medicine, Japan
  2. Division of Histology and Cell Biology, Department of Anatomy, Jichi Medical University School of Medicine, Japan
  3. Department of Anatomy, Graduate School of Medicine, Teikyo University, Japan
  4. Department of Clinical Proteomics, National Cancer Center Research Institute, Japan
https://doi.org/10.7554/eLife.57381
Share this article
Cite this article
  1. Saishu Yoshida
  2. Katsuhiko Aoki
  3. Ken Fujiwara
  4. Takashi Nakakura
  5. Akira Kawamura
  6. Kohji Yamada
  7. Masaya Ono
  8. Satomi Yogosawa
  9. Kiyotsugu Yoshida
(2020)
The novel ciliogenesis regulator DYRK2 governs Hedgehog signaling during mouse embryogenesis
eLife 9:e57381.
https://doi.org/10.7554/eLife.57381
  2. Download BibTeX
  3. Download .RIS

Abstract

Mammalian Hedgehog (Hh) signaling plays key roles in embryogenesis and uniquely requires primary cilia. Functional analyses of several ciliogenesis-related genes led to the discovery of the developmental diseases known as ciliopathies. Hence, identification of mammalian factors that regulate ciliogenesis can provide insight into the molecular mechanisms of embryogenesis and ciliopathy. Here, we demonstrate that DYRK2 acts as a novel mammalian ciliogenesis-related protein kinase. Loss of Dyrk2 in mice causes suppression of Hh signaling and results in skeletal abnormalities during in vivo embryogenesis. Deletion of Dyrk2 induces abnormal ciliary morphology and trafficking of Hh pathway components. Mechanistically, transcriptome analyses demonstrate down-regulation of Aurka and other disassembly genes following Dyrk2 deletion. Taken together, the present study demonstrates for the first time that DYRK2 controls ciliogenesis and is necessary for Hh signaling during mammalian development.

Introduction

Embryogenesis and patterning of cell differentiation are facilitated by spatiotemporal activation of multiple signaling pathways. The Hedgehog (Hh) signaling is an evolutionarily conserved system that plays a central role in embryogenesis via regulating cell proliferation and differentiation (Ingham and McMahon, 2001). Upon stimulation by ligands, post-translational modification of GLI2 and GLI3 induces the expression of Gli1, which is a key amplifier of Hh signaling. These post-translational and transcriptional activations of three GLIs regulate specific and redundant target genes (Mo et al., 1997; Hui and Angers, 2011). Hence, mutants of Hh components cause typical defects such as skeletal, neural, and retinal abnormalities (Mo et al., 1997).

Unlike other core developmental signaling, vertebrate Hh signaling is uniquely and completely dependent upon primary cilia, which are microtubule-based organelles that are formed during the G0 or G1 phases of the cell cycle (Huangfu et al., 2003). Binding of Hh ligands to Patched 1 (PTCH1) on cilia leads to activation and induction of Seven-spanner smoothened (SMO) to the cilia (Rohatgi et al., 2007). Activated SMO leads to recruitment of GLI2 and GLI3 to the cilia tip via inhibition of protein kinase A (Chen et al., 2009; Kim et al., 2009; Wen et al., 2010). This dynamic ciliary trafficking of Hh components is primarily regulated by intraflagellar transport (IFT) (Haycraft et al., 2005; Eguether et al., 2014). Thus, ciliogenesis is indispensable for tissue development, and defects in this process impact the development of multiple organs to cause human and mouse diseases termed ‘ciliopathies’ (Reiter and Leroux, 2017). Accordingly, the typical phenotype observed in some of ciliopathies such as Joubert syndrome is abnormalities of Hh signaling (Bangs and Anderson, 2017).

Mutations in a number of different ciliopathy-associated genes often result in alterations of ciliary length (Paige Taylor et al., 2016; Reiter and Leroux, 2017). Indeed, genetic screenings of Chlamydomonas, which is a model organism for ciliogenesis, have identified the ciliopathy-associated genes controlling cilia length to generate the optimal length at steady-state (Wemmer and Marshall, 2007). Although these abnormalities in ciliary length are thought to be controlled by the balance of assembly and disassembly via IFT and a postulated length sensor, the mechanisms for maintaining the cell-type-specific ciliary length have not been fully elucidated (Ishikawa and Marshall, 2011). In contrast, the ciliary resorption mechanisms for cell cycle re-entry have been thoroughly investigated by such as an experiment of serum re-addition to starved cells, and these mechanisms include the HEF1-AURKA-HDAC6 pathway (Pugacheva et al., 2007), the PLK-KIF2A pathway (Wang et al., 2013), and the NEK2-KIF24 pathway (Kobayashi et al., 2011; Kim et al., 2015b) that have been observed to induce disassembly of cilia. On the other hand, the ability of these ciliary resorption factors for cell cycle re-entry to control cilia length at steady-state and during ciliogenesis remains to be elucidated. Hence, identification of novel mammalian factors regulating ciliogenesis and ciliary length control will provide insight into the molecular mechanisms underlying embryogenesis and ciliopathy as well as ciliary functions.

Dual-specificity tyrosine-regulated kinase (DYRK) is a family that belongs to the CMGC group that includes cyclin-dependent kinases (CDK), mitogen-activated protein kinase (MAPK), glycogen synthase kinase (GSK), and CDK-like kinase (CLKs) (Becker and Sippl, 2011). Two isoforms of Dyrk2 have been identified; long and short forms, the latter lacks a 5’ terminal region. In human cancer cells, we have functionally identified DYRK2 as a regulator of p53-induced apoptosis in response to DNA damage (Taira et al., 2007) and of G1/S transition (Taira et al., 2012). During development in lower eukaryotes, MBK2, which is an ortholog of DYRK2 in Caenorhabditis elegans, regulates maternal-protein degradation during the oocyte-to-embryo transition via a ubiquitin-dependent mechanism (Pellettieri et al., 2003; Pang et al., 2004; Lu and Mains, 2007; Yoshida and Yoshida, 2019). While these reports lead us to speculate that DYRK2 must also play important roles in mammalian development, no reports are available regarding the mechanistic role of DYRK2 in vivo.

In the present study, we aim to reveal a function for DYRK2 in mammalian development in vivo. Here, we demonstrate that DYRK2 is a novel regulator of ciliogenesis and is required for normal embryogenesis via activation of Hh signaling during development.

Results

Dyrk2 deficiency cause suppression of Hedgehog signaling during mouse embryogenesis

We generated Dyrk2 knockout mice (Dyrk2-/-) by eliminating the third exon of the Dyrk2 genomic locus (Figure 1—figure supplement 1A–B). The absence of DYRK2 protein in homozygous Dyrk2-/- mice was confirmed (Figure 1—figure supplement 1C). Although the gross morphology of homozygous Dyrk2-/- embryos appeared normal during early development, multiple defects became obvious during later stages of gestation, and the mice died at or close to birth (Figure 1A). Specifically, defects in skeletal development were remarkable, and these included a shorter dorsum of the nose (Figure 1A), cleft palate including hypoplasia of the tongue (Figure 1B–C), loss of the basisphenoid, basioccipital, and presphenoid bones (Figure 1D), shorter limbs (Figure 1E), defects of segmentation of the sternebrae in the sternum (Figure 1F), and vertebra (Figure 1G) at embryonic day (E) 18.5. These skeletal defects that included reduction of bone mineralization were observed until E16.5 (Figure 1H).

Figure 1 with 1 supplement see all
Download asset Open asset
Deletion of DYRK2 shows skeletal defects in mouse development.

(A) Whole embryo gross images of wild-type and homozygous Dyrk2-/- embryos at birth. (B, C) Palatal and tongue abnormalities in Dyrk2-/- embryos. Gross images of the palate with mandible removed from wild-type and Dyrk2-/- embryos at E18.5 (B), and HE staining from the coronal plane at E13.5 (C). Dotted lines in (B) and an asterisk in (C) indicate cleft of the secondary palate. (D–H) Arizarin red and alcian blue staining of the craniofacial skeleton (D), forelimbs (E), sternum (F), and vertebra (G) from wild-type and Dyrk2-/- embryos at E18.5, and whole skeleton staining at E16.5 (H). Arrowheads in (H) indicate regions that decreasing bone mineralization. bo, basioccipital bone; bs, basisphenoid; h, humerus; r, radius; p, palatal shelves; ps, presphenoid; s, scapula; st, sternebrae; t, tongue; u, ulna. Scale bars, 5 mm.

As Dyrk2-/- embryos at E18.5 exhibited a similar phenotype to that observed in response to certain defects in Hh signaling (Mo et al., 1997), we assessed Gli1-expression, which is an indicator of Hh signaling activation (Niewiadomski and Rohatgi, 2015). In situ hybridization demonstrated that Gli1-expression was decreased in the craniofacial region in Dyrk2-/- embryos at E14.5 (Figure 2A). Protein levels of GLI1 were also decreased at E13.5 (Figure 2B). Ptch1-expression, which is another indicator of Hh signaling activation (Snouffer et al., 2017), was also decreased in Dyrk2-/- embryos at E13.5, and this was accompanied by a decrease in Gli1; however, Shh-expression remained unchanged (Figure 2C). We also observed a repression of Foxf2-expression, which is a direct target gene of GLI1 (Everson et al., 2017), in the craniofacial region of Dyrk2-/- embryos (Figure 2D–E).

Figure 2 with 1 supplement see all
Download asset Open asset
Deletion of DYRK2 affects activation of Hh signaling in mouse development.

(A) In situ hybridization of Gli1 in the craniofacial region in wild-type and Dyrk2-/- embryos from the sagittal plane at E14.5. (B) Immunoblotting of GLI1 in extracts from the limbs of wild-type and Dyrk2-/- embryos at E13.5. GAPDH serves as a loading control. (C) qPCR of Gli1, Ptch1, and Shh in the limbs from wild-type and Dyrk2-/- embryos at E13.5. (D, E) Repression of Foxf2-expression in the craniofacial region of Dyrk2-/- mice. (D) In situ hybridization of Foxf2 in the craniofacial region in wild-type and Dyrk2-/- embryos from the sagittal plane at E14.5. (E) qPCR of Foxf2 in the mandibular arch from wild-type and Dyrk2-/- embryos at E10.5. Hypoxanthine phosphoribosyltransferase (Hprt) in (C and E) was used as an internal standard, and fold change was calculated by comparing expression levels relative to those of wild-type. Data are presented as the means ± SEM (n = 3 biological replicates). The statistical significance between wild-type and Dyrk2-/- was determined by the Student’s t-test. (*) p<0.05, (**) p<0.01. t, tongue; ul, upper lip. Scale bars, 500 µm.

Figure 2—source data 1

Source data for Figure 2C and E.

https://cdn.elifesciences.org/articles/57381/elife-57381-fig2-data1-v1.xlsx

Loss of genes required for Hh signaling often causes defects in dorsal-ventral neural tube patterning, which is regulated by the SHH morphogen (Dessaud et al., 2008). Although we investigated the localization patterns of FOXA2, NKX2.2, OLIG2, NKX6.1, and PAX6 at E10.5, we did not observe obvious differences in their expression patterns (Figure 2—figure supplement 1A). Expression of Hh target genes was decreased in Dyrk2-/- whole embryos at E9.5 (Figure 2—figure supplement 1B). In situ hybridization demonstrated that Ptch1-expression was decreased in the mandibular arch in Dyrk2-/- embryos at E10.5, but remained unchanged in the neural tube (Figure 2—figure supplement 1C). These data showing the maintenance of Hh signal and dorsal-ventral patterning in the neural tube might correspond to a spatiotemporal expression-pattern of Dyrk2.

Taken together, Dyrk2-deficient embryos exhibit a robust suppression of Hh signaling and possess particular skeletal abnormalities during embryogenesis.

DYRK2 positively regulates Hh signaling

To investigate the defect in Hh signaling in Dyrk2-/- mice in more detail, we analyzed primary mouse embryonic fibroblasts (MEFs) derived from wild-type and Dyrk2-/- mice. First, we measured Hh signaling activity in response to stimulation with the SMO agonist SAG. In response to stimulation with SAG, Gli1 and Ptch1 expression was increased in wild-type mice as previously reported (Figure 3A; Niewiadomski and Rohatgi, 2015). In contrast, in Dyrk2-/- MEFs, inductions of both Gli1 and Ptch1 expression by SAG was drastically repressed (Figure 3A). Consistent with gene expression analyses, the induction of GLI1 protein by SAG stimulation was also suppressed in Dyrk2-/- MEFs (Figure 3B). Immunocytostaining for GLI1 following stimulation with SAG demonstrated that the accumulation of GLI1 protein within nuclei was clearly diminished in Dyrk2-/- MEFs (Figure 3C). To validate whether these phenotypes observed in Dyrk2-/- MEFs are due to abnormal differentiation caused by deletion of Dyrk2 during early embryogenesis, we performed a transient knockdown of Dyrk2 in wild-type MEFs using two independent short interfering RNAs (siRNAs). Transient knockdown of Dyrk2 also demonstrated suppression of both the mRNA and protein levels of Gli1 and Ptch1 in response to stimulation with SAG (Figure 3—figure supplement 1A–B).

Figure 3 with 2 supplements see all
Download asset Open asset
Deletion of Dyrk2 suppresses activation of Hh signaling in vitro.

(A) Expression of the Hh target genes Gli1 and Ptch1 in wild-type and Dyrk2-/- MEFs in the absence or presence of 100 nM SAG was measured by qPCR. Data are shown as relative expression to Hprt. (B) Protein levels of GLI1 and DYRK2 in wild-type and Dyrk2-/- MEFs in the absence or presence of 100 nM SAG were measured by immuno-blotting. L and S indicate long and short transcriptional isoforms of DYRK2, respectively. (C) Wild-type and Dyrk2-/- MEFs in the absence or presence of 100 nM SAG were immune-cytostained for GLI1 (red). Nuclei were stained with DAPI (blue). Scale bars, 5 µm. (D) Expression of Gli1 and Ptch1 in Dyrk2-/- MEFs overexpressing human DYRK2 or DYRK2-K251R (kinase dead) constructs via adenovirus infection was measured by qPCR. Data indicates fold induction of 100 nM SAG against vehicle after normalization to Hprt. (E, F) Immunoblotting for GLI2 in wild-type and Dyrk2-/- MEFs in the absence or presence of 100 nM SAG. Protein level as fold changes of GLI2 (E) was calculated by comparing protein levels relative to those of wild-type MEFs in the absence of SAG after normalization to the GAPDH loading control in (F). Data are presented as the means ± SEM (n = 5, 3, and 4 biological replicates per condition in A, D, and F, respectively). The statistical significance was determined by one-way ANOVA followed by Tukey’s multiple comparison test. (*) p<0.05, (**) p<0.01.

Figure 3—source data 1

Source data for Figure 3A and D.

https://cdn.elifesciences.org/articles/57381/elife-57381-fig3-data1-v1.xlsx
Figure 3—source data 2

Source data for Figure 3F.

https://cdn.elifesciences.org/articles/57381/elife-57381-fig3-data2-v1.xlsx

To validate this suppression of Hh signaling by Dyrk2-deletion, we performed a transient over-expression experiment using wild-type human DYRK2 or a DYRK2-K251R construct that expresses a kinase dead mutant (Taira et al., 2012; Figure 3—figure supplement 1C–D) in Dyrk2-/- MEFs using adenovirus infection (Yokoyama-Mashima et al., 2019). Over-expression of the wild-type DYRK2 construct restored significant induction of Gli1 and Ptch1 expression upon exposure to SAG (Figure 3D, Figure 3—figure supplement 1D). In sharp contrast, over-expression of the DYRK2-K251R construct in Dyrk2-/- MEFs markedly diminished Gli1 and Ptch1 expression (Figure 3D). Additionally, over-expression of the DYRK2-K251R construct slightly increased Gli1 and Ptch1 expression in comparison with that of empty vector (Figure 3D). This kinase-independent effect might be associated with a function of DYRK2 as a scaffold protein (Maddika and Chen, 2009). Taken together, the induction of Hh signaling is drastically suppressed by deletion of Dyrk2 in a kinase activity-dependent manner.

The key Hh pathway components GLI2 and GLI3 are known to be posttranslationally modified in a manner that is dependent upon Hh ligands (Mo et al., 1997; Hui and Angers, 2011). In the absence of Hh ligands, the full-length proteins (active forms; GLI2 and GLI3FL) are phosphorylated by multiple kinases, leading to proteasomal degradation or truncation into N-terminal repressor forms (GLI3REP), respectively (Niewiadomski and Rohatgi, 2015). In this context, we analyzed the endogenous protein levels and states of GLI2 and GLI3. In wild-type MEFs, immunoblotting for GLI2 revealed that full-length form of GLI2 was increased by SAG-stimulation (Figure 3E–F). In contrast to wild-type MEFs, the increase of GLI2 protein levels by SAG was significantly suppressed in Dyrk2-/- MEFs (Figure 3E–F). We also analyzed two forms of GLI3 (GLI3FL and GLI3REP). SAG-stimulation suppressed the formation of GLI3REP and decreased the ratio of GLI3REP/GLI3FL in wild-type MEFs (Figure 3—figure supplement 2; Niewiadomski and Rohatgi, 2015). In Dyrk2-/- MEFs, however, we found that the ratio of GLI3REP/GLI3FL was marginally suppressed and that no significant differences between the absence or presence of SAG existed (Figure 3—figure supplement 2D). Collectively, these data indicate that the deletion of Dyrk2 affects the stabilities of GLI2, and marginally GLI3, under SAG-stimulation.

DYRK2 regulates ciliogenesis

As primary cilia are essential organelles required for signal transduction of vertebrate Hh signaling (Huangfu et al., 2003), we investigated whether DYRK2 regulates ciliogenesis in MEFs. Immunostaining of acetylated tubulin (a cilia axoneme marker) and γ-tubulin (a basal body marker) demonstrated that the length of primary cilia in Dyrk2-/- MEFs was significantly longer than that in wild-type MEFs (Figure 4A). The average cilia length in wild-type MEFs was 1.65 ± 0.03, while it was 3.59 ± 0.08 in Dyrk2-/- MEFs (Figure 4B–C). In addition to the increased length, the morphology of primary cilia in Dyrk2-/- MEFs was often bulged at the tips, tapered, and twisted (Figure 4A). This elongation and morphological abnormality of primary cilia was similarly observed in response to the transient knockdown of Dyrk2 by siRNA in wild-type MEFs (Figure 4—figure supplement 1). To investigate whether the regulation of ciliogenesis by DYRK2 is conserved in other species and cell types, we analyzed immortalized human retinal pigment epithelia cells (hTERT-RPE1 cells) that are commonly used to study cilia-assembly and -disassembly. A transient knockdown by siDYRK2 also induced a significant elongation and morphological abnormality in cilia of these cells (Figure 4—figure supplement 2). In contrast to the length and morphology of primary cilia, no difference was observed on the proportion of ciliated cells in wild-type and Dyrk2-/- MEFs (Figure 4—figure supplement 3A–B). Similarly, in cell-cycling (KI67-positive) wild-type and Dyrk2-/- MEFs, there was comparable in the proportion of ciliated cells (ciliated cells in KI67-positive cells is 1 per 199 and 1 per 139 cells in wild-type and Dyrk2-/- MEFs, respectively) (Figure 4—figure supplement 3C).

Figure 4 with 3 supplements see all
Download asset Open asset
DYRK2 constrains the length of primary cilia.

(A–C) Elongation of primary cilia in Dyrk2-/- MEFs. Primary cilia of wild-type and Dyrk2-/- MEFs were immunostained with acetylated-tubulin and gamma-tubulin antibodies. (B, C) Measurements of cilia length in wild-type and Dyrk2-/- MEFs using acetylated-tubulin as a cilia axoneme marker. Cilia lengths are presented as pooled from five MEFs derived from independent embryos of each genotype (B) and the average of each MEF (C). Data are presented as the means ± SEM (n = 5 biological replicates per condition). The statistical significance between wild-type and Dyrk2-/- was determined by the Student’s t-test. (**) p<0.01. (D) Scanning electron microscopy showing wild-type and Dyrk2-/- embryos in the frontonasal prominence at E10.5. (E) Immunohistochemistry of primary cilia in wild-type and Dyrk2-/- embryos. ARL13B was immuno-stained in wild-type and Dyrk2-/- mesenchymal cells at the craniofacial region at E13.5. Nuclei were stained with DAPI. Scale bars, 5 µm (A and E) and 1 µm (D).

Figure 4—source data 1

Source data for Figure 4B–C.

https://cdn.elifesciences.org/articles/57381/elife-57381-fig4-data1-v1.xlsx

To confirm the morphological abnormalities of primary cilia within the tissue, we performed scanning electron microscopy (SEM) on embryos at E10.5. SEM images clearly showed that the cilia of Dyrk2-/- embryos were significantly elongated, bulged at the tips, and twisted, while those of wild-type embryos were shortened and straight (Figure 4D). These abnormalities were also observed in several types of cells, including mesenchymal cells (Figure 4E), chondrocytes, neuroepithelium, and tongue cells (data not shown) in the embryonic craniofacial region at E13.5 as assessed by immunohistochemistry.

These data indicating that deletion of Dyrk2 causes morphological abnormalities in primary cilia prompted us to determine the subcellular localization of DYRK2. We transfected DYRK2-HaloTag constructs into hTERT-RPE1 cells and induced ciliogenesis by serum-starvation. Immunocytostaining for both anti-HaloTag and anti-DYRK2 revealed that DYRK2 localized at γ-tubulin-positive basal bodies and at the proximal end of the axoneme, namely a transition zone (TZ) (Figure 5A–B). No signal for anti-HaloTag (Figure 5C) or anti-DYRK2 (data not shown) was observed in hTERT-RPE1 cells transfected with empty vector (pFN22K-Halo Tag-CMVd1-Flexi-vector). Moreover, immuno-positive signals for DYRK2-HaloTag were co-localized with a TZ marker, NPHP1 (Figure 5D).

Figure 5
Download asset Open asset
DYRK2 localizes at basal bodies and transition zone (TZ) in primary cilia.

Cultured hTERT-RPE1 cells were transfected with a mouse DYRK2-HaloTag overexpression construct and immunostained using anti-HaloTag (A) or anti-DYRK2 (B) with acetylated-tubulin (white) and gamma-tubulin antibodies. (C) Cultured hTERT-RPE1 cells transfected with an empty vector (pFN22K-Halo Tag-CMVd1-Flexi-vector) and immunostained using anti-HaloTag with acetylated-tubulin (white) and gamma-tubulin antibodies. (D) Co-localization of DYRK2 and a TZ marker, NPHP1. Cultured hTERT-RPE1 cells overexpressed with a mouse DYRK2-HaloTag were immunostained using anti-HaloTag, NPHP1 (white), and gamma-tubulin antibodies. Nuclei were stained with DAPI. Scale bars, 5 µm.

These data indicated that DYRK2 might regulate ciliogenesis at basal bodies and TZ in vivo and in vitro.

Deletion of DYRK2 induces abnormal ciliary trafficking of Hedgehog pathway components

In mammals, key regulators of Hh signaling have been demonstrated to be recruited and activated at the cilia upon Hh stimulation (Chen et al., 2009; Kim et al., 2009; Tukachinsky et al., 2010; Wen et al., 2010), and disorders in the ciliary trafficking of Hh components cause dysfunction of Hh signaling (He et al., 2014). To investigate whether inactivation of Hh signaling in Dyrk2-/- embryos and MEFs is due to abnormal ciliary trafficking of Hh components, we analyzed the ciliary localization of key regulators such as SMO, GLI2, GLI3, and SuFu. In wild-type MEFs, immuno-positive SMO signals were mostly undetectable or faint in the absence of Hh stimulation, and recruitment to cilia was dependent upon Hh stimulation (Figure 6A–B), as shown in a previous report (Tukachinsky et al., 2010). Similarly, no significant difference in the frequency of SMO recruitment in response to SAG stimulation was observed in Dyrk2-/- MEFs (Figure 6A–B).

Figure 6 with 4 supplements see all
Download asset Open asset
Depletion of Dyrk2 induces abnormal ciliary trafficking of endogenous Hh components.

Ciliary localization of endogenous SMO, GLI2, and GLI3 in wild-type and Dyrk2-/- MEFs in the absence or presence of 100 nM SAG. Primary cilia were immuno-stained for SMO (A), GLI2 (C), or GLI3 (E) with ARL13B and gamma-tubulin (white) antibodies. Nuclei were stained with DAPI (blue). The percentage of cells with SMO (B) at the cilia or foci of GLI2 (D) or GLI3 (F) at the cilia tips was determined. Data are presented as the means ± SEM (n = 3 biological replicates for each condition;>110 cells were scored for each experiment). The statistical significance was determined by one-way ANOVA followed by Tukey’s multiple comparison test. (*) p<0.05, (**) p<0.01. Scale bars, 5 µm.

Figure 6—source data 1

Source data for Figure 6B,D and F.

https://cdn.elifesciences.org/articles/57381/elife-57381-fig6-data1-v1.xlsx

We subsequently analyzed the ciliary localization of endogenous GLI2 and GLI3. As shown in a previous report (Tukachinsky et al., 2010), in wild-type MEFs, immuno-positive signals for both GLI2 and GLI3 were mostly undetectable or faint in the absence of Hh stimulation, and SAG stimulation increased the presence of GLI2 and GLI3 at cilia tips (Figure 6C–F). In contrast, in Dyrk2-/- MEFs, immuno-positive signals for both GLI2 (approximately 75.9% of cilia) and GLI3 (approximately 95.8%) were observed at cilia tip even in the absence of SAG treatment (Figure 6C–F). Moreover, the intensity of immune-positive signals was markedly increased by SAG-treatment in Dyrk2-/- MEFs (Figure 6C,E). These accumulations at cilia tips were frequently observed in Dyrk2-/- mesenchymal cells in the craniofacial region at E10.5 tissues but were absent in wild-type cells (Figure 6—figure supplement 1). Additionally, localization of SuFu, which forms a complex with both GLI2 and GLI3 (Tukachinsky et al., 2010), was disordered in cilia tips in a similar pattern to that of GLI2 and GLI3 (Figure 6—figure supplement 2A). Collectively, ciliary localization of GLI2, GLI3, and SuFu in Dyrk2-/- MEFs and embryos was clearly disordered and was accumulated at cilia tips. Importantly, the recruitment of GLI2, GLI3, and SuFu in response to SAG stimulation was also observed in Dyrk2-/- MEFs.

Inhibition of retrograde transport from the tip to the cell body induces accumulation of Hh components and results in abnormal localization of both IFT-A (implicated in retrograde IFT) and IFT-B (implicated in anterograde) (Ocbina and Anderson, 2008; Ocbina et al., 2011; Liem et al., 2012). Based on this, we analyzed the ciliary localization of core IFT-A (IFT140) and IFT-B (IFT81 and IFT88) (Nakayama and Katoh, 2018). In Dyrk2-/- MEFs, no obvious differences in ciliary localization of IFT140, IFT81, and IFT88 were observed (Figure 6—figure supplement 2B–D).

Activation of mammalian target of rapamycin complex 1 (mTORC1) also induces abnormal trafficking and elongates cilia length (Broekhuis et al., 2014). mTORC1 activation leads to phosphorylation of ribosomal S6 kinase (S6K) and eukaryotic translational initiation factor 4E binding protein (4EBP). In Dyrk2-/- MEFs, phosphorylation of both S6K and 4EBP was slightly increased (Figure 6—figure supplement 3A); however, treatment with rapamycin, an inhibitor of mTORC1, resulted in no obvious differences in cilia length in Dyrk2-/- MEFs (Figure 6—figure supplement 3B–D).

Moreover, a centrosome protein CP110 (Hossain et al., 2017) and a microtubule severing enzyme, KATANIN p60 (Maddika and Chen, 2009), have been identified as substrates of DYRK2 for proteolysis. In Dyrk2-/- MEFs, however, no obvious difference in protein levels of both CP110 and KATANIN p60 was observed (Figure 6—figure supplement 4).

Deletion of Dyrk2 dysregulates the expression of Aurka and other cilia-disassembly genes

To understand the molecular mechanisms underlying cilia dysfunction in Dyrk2-/- mice, we focused on factors that are involved in ciliary length control by incorporating whole-genome RNA sequencing using wild-type and Dyrk2-/- MEFs (Figure 7, Figure 7—figure supplement 1). The data were analyzed by multiple testing and according to p-value, false discovery rate (FDR), and ratio (Dyrk2-/-/wild-type). As a result, the number of identified genes was 53 or 42 that were significantly downregulated (p<0.005, ratio <1.5 fold) or upregulated (p<0.005, ratio >1.5 fold) in Dyrk2-/- MEFs, respectively, regardless of the presence or absence of SAG (Table 1). Notably, GO and STRING analysis revealed that the 53 downregulated genes in Dyrk2-/- MEFs were enriched in cell division (GO: 0051301, FDR = 5.17E-40), microtubule cytoskeleton organization (GO:0000226, FDR = 5.23E-15), spindle organization (GO:0007051, FDR = 2.72E-11), mitotic cell cycle checkpoint (GO:0007093, FDR = 3.78E-07), and microtubule-based movement (GO:0007018, FDR = 3.9E-4) (Figure 7A, Figure 7—figure supplement 1B). These downregulated genes in Dyrk2-/- MEFs included those related to ciliary resorption mechanisms for proliferation, including the HEF1-AURKA-HDAC6 pathway (Aurka, Plk1, Ube2c, and Tpx2) (Pugacheva et al., 2007), the PLK-KIF2A pathway (Plk1 and Kif2c, a family of Kif2a) (Wang et al., 2013), and the APCCDC20-Nek1 pathway (Cdc20) that controls ciliary length (Wang et al., 2014; Keeling et al., 2016). We confirmed the downregulation of Aurka, Plk1, Ube2c, Tpx2, Kif2c, and Cdc20 in Dyrk2-/- MEFs by qPCR (Figure 7B). To identify a molecule involved in cilia-elongation in Dyrk2-/- cells, we performed transient knockdown of selected genes using siRNA in wild-type MEFs, and we analyzed cilia length. Notably, we found that knockdown of Aurka by two independent siRNAs significantly increases cilia length (Figure 8). Moreover, we performed a rescue experiment by over-expression of AURKA-EGFP in Dyrk2-/- MEFs (Figure 9). Immunostaining and measurement of the cilia length in EGFP- (transfected with pEGFP-C1) or AURKA-EGFP-positive (transfected with Aurka/pEGFP-C1) Dyrk2-/- MEFs demonstrated that elongated cilia in Dyrk2-/- MEFs were significantly shortened in AURKA-EGFP-positive cells in comparison with EGFP-positive ones (Figure 9D–G).

Figure 7 with 1 supplement see all
Download asset Open asset
Changes in mRNA expression of genes in Dyrk2-/- MEFs.

(A) STRING GO analyses of the 53 differentially downregulated genes in Dyrk2-/- MEFs reveals protein-protein interaction networks. Robust networks for cell division (green, GO: 0051301), microtubule cytoskeleton organization (red, GO:0000226), spindle organization (yellow, GO:0007051), mitotic cell cycle checkpoint function (purple, GO:0007093), and microtubule-based movement (blue, GO:0007018) were extracted. (B) Confirmation of downregulation of genes related to ciliary resorption mechanisms in Dyrk2-/- MEFs by qPCR. Hprt was used as an internal standard, and fold change was calculated by comparing expression levels relative to those of wild-type. Data are presented as the means ± SEM (n = 3 biological replicates per condition). The statistical significance between wild-type and Dyrk2-/- MEFs was determined using the Student’s t-test. (*) p<0.05.

Figure 7—source data 1

Source data for Figure 7B.

https://cdn.elifesciences.org/articles/57381/elife-57381-fig7-data1-v1.xlsx
Figure 8
Download asset Open asset
Elongation of primary cilia in wild-type MEFs treated with siAurka.

(A) Immunoblotting of AURKA in wild-type and Dyrk2-/- MEFs. GAPDH serves as a loading control. (B) Knockdown efficiency of Aurka-expression in wild-type MEFs treated with two independent siAurka for 48 hr was measured by qPCR. Hprt was used as an internal standard, and fold change was calculated by comparing expression levels relative to those of siNegative (siNeg.). Data are presented as the means ± SEM (n = 3 biological replicates per condition). (C) Primary cilia in wild-type cells treated with siNegative (siNeg.) or two independent siAurka were immuno-stained with ARL13B and gamma-tubulin antibodies. Scale bars, 5 µm. (D, E) Measurements of cilia length in wild-type MEFs treated with siNeg. or two independent siAurka using ARL13B and acetylated-tubulin as a cilia axoneme marker. Cilia lengths are presented as pooled from four MEFs derived from independent wild-type embryos (D) and represent an average of each MEF (E). Data are presented as the means ± SEM (n = 4 biological replicates per condition). The statistical significance was determined by one-way ANOVA followed by Tukey’s multiple comparison test. (**) p<0.01.

Figure 8—source data 1

Source data for Figure 8B and D–E.

https://cdn.elifesciences.org/articles/57381/elife-57381-fig8-data1-v1.xlsx
Figure 9
Download asset Open asset
Reduction of the length of primary cilia in Dyrk2-/- MEFs by over-expression of AURKA.

(A–C) Immunoblotting by anti-AURKA (A), anti-GFP (B), and anti-GAPDH (C) in cells transfected with pEGFP-C1 or mouse Aurka/pEGFP-C1. GAPDH serves as a loading control. (D, E) Primary cilia in Dyrk2-/- MEFs over-expressed with EGFP (D) or AURKA-EGFP (E) were immunostained with GFP, ARL13B, and gamma-tubulin (white) antibodies. Arrowheads in (E) indicate signals for AURKA-EGFP in gamma-tubulin-positive basal body. Scale bars, 5 µm. (F, G) Measurements of cilia length in EGFP- or AURKA-EGFP-over-expressed Dyrk2-/- MEFs using ARL13B as a cilia axoneme marker. Cilia lengths in EGFP- or AURKA-EGFP-positive cells are presented as pooled from three MEFs derived from independent Dyrk2-/- embryos (F) and represent an average of each MEF (G). Data are presented as the means ± SEM (n = 3 biological replicates per condition). The statistical significance between EGFP- and AURKA-EGFP-positive cells was determined by the Student’s t-test. (**) p<0.01.

Figure 9—source data 1

Source data for Figure 9F and G.

https://cdn.elifesciences.org/articles/57381/elife-57381-fig9-data1-v1.xlsx
Table 1
A list of downregulated or upregulated genes in Dyrk2-/- MEFs
Down-regulated genes in Dyrk2-/-
IDGeneSymbolDescriptionRatio of Dyrk2-/-per wild-type in the presence of SAGRatio of Dyrk2-/-per wild-type in the absence of SAG
ENSMUSG00000028630Dyrk2Dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 20.020.03
ENSMUSG00000035683MelkMaternal embryonic leucine zipper kinase0.230.22
ENSMUSG00000074476Spc24NDC80 kinetochore complex component%2C homolog (S. cerevisiae)0.250.21
ENSMUSG00000020808PimregPICALM interacting mitotic regulator0.280.28
ENSMUSG00000033952AspmAbnormal spindle microtubule assembly0.310.25
ENSMUSG00000026683Nuf2NDC80 kinetochore complex component0.310.30
ENSMUSG00000037466Tedc1Tubulin epsilon and delta complex 10.310.26
ENSMUSG00000030867Plk1Polo-like kinase 10.310.17
ENSMUSG00000022033PbkPDZ binding kinase0.330.29
ENSMUSG00000027326Knl1Kinetochore scaffold 10.330.20
ENSMUSG00000041431Ccnb1Cyclin B10.330.26
ENSMUSG00000036777AnlnAnillin actin binding protein0.330.26
ENSMUSG00000001403Ube2cUbiquitin-conjugating enzyme E2C0.330.25
ENSMUSG00000027496AurkaAurora kinase A0.340.26
ENSMUSG00000001349Cnn1Calponin 10.340.31
ENSMUSG00000032218Ccnb2Cyclin B20.340.28
ENSMUSG00000026039Sgo2aShugoshin 2A0.340.25
ENSMUSG00000015880NcapgNon-SMC condensin I complex subunit G0.340.34
ENSMUSG00000027379Bub1BUB1 mitotic checkpoint serine/threonine kinase0.360.23
ENSMUSG00000040084Bub1bBUB1B mitotic checkpoint serine/threonine kinase0.360.29
ENSMUSG00000045328CenpeCentromere protein E0.360.22
ENSMUSG00000032254Kif23Kinesin family member 230.370.25
ENSMUSG00000028873Cdca8Cell division cycle associated 80.370.30
ENSMUSG00000032135McamMelanoma cell adhesion molecule0.370.29
ENSMUSG00000027469Tpx2TPX2microtubule-associated0.370.33
ENSMUSG00000028678Kif2cKinesin family member 2C0.370.24
ENSMUSG00000027715Ccna2Cyclin A20.380.23
ENSMUSG00000048327Ckap2lCytoskeleton associated protein 2-like0.390.23
ENSMUSG00000040204PclafPCNA clamp associated factor0.400.19
ENSMUSG00000029414Kntc1Kinetochore associated 10.420.24
ENSMUSG00000034311Kif4Kinesin family member 40.420.24
ENSMUSG00000031004Mki67Antigen identified by monoclonal antibody Ki 670.420.21
ENSMUSG00000020914Top2aTopoisomerase (DNA) II alpha0.420.21
ENSMUSG00000033031Cip2aCell proliferation regulating inhibitor of protein phosphatase 2A0.420.32
ENSMUSG00000035783Acta2Actin alpha two smooth muscle aorta0.430.48
ENSMUSG00000024795Kif20bKinesin family member 20B0.430.30
ENSMUSG00000038943Prc1Protein regulator of cytokinesis 10.430.26
ENSMUSG00000026494Kif26bKinesin family member 26B0.430.25
ENSMUSG00000023015Racgap1Rac GTPase-activating protein 10.430.26
ENSMUSG00000026605CenpfCentromere protein F0.440.25
ENSMUSG00000027306Nusap1Nucleolar and spindle associated protein 10.450.28
ENSMUSG00000028068Iqgap3IQ motif containing GTPase activating protein 30.460.21
ENSMUSG00000003779Kif20aKinesin family member 20A0.470.25
ENSMUSG00000005410Mcm5Minichromosome maintenance complex component 50.470.26
ENSMUSG00000034906NcaphNon-SMC condensin I complex subunit H0.470.27
ENSMUSG00000006398Cdc20Cell division cycle 200.480.29
ENSMUSG00000037313Tacc3Transforming acidic coiled-coil containing protein 30.480.36
ENSMUSG00000027699Ect2ect2 oncogene0.480.26
ENSMUSG00000020330HmmrHyaluronan-mediated motility receptor (RHAMM)0.500.28
ENSMUSG00000020649Rrm2Ribonucleotide reductase M20.500.26
ENSMUSG00000019942Cdk1Cyclin-dependent kinase 10.500.34
ENSMUSG00000024590Lmnb1Lamin B10.510.33
ENSMUSG00000037725Ckap2Cytoskeleton associated protein 20.550.42
Upregulated genes in Dyrk2-/-
IDGeneSymbolDescriptionRatio of Dyrk2-/-per wild-type in the presence of SAGRatio of Dyrk2-/-per wild-type in the absence of SAG
ENSMUSG00000056673Kdm5dLysine (K)-specific demethylase 5DInfInf
ENSMUSG00000068457UtyUbiquitously transcribed tetratricopeptide repeat gene Y chromosomeInfInf
ENSMUSG00000069049Ddx3yDEAD (Asp-Glu-Ala-Asp) box polypeptide 3 Y-linkedInf8278
ENSMUSG00000069045Eif2s3yEukaryotic translation initiation factor 2 subunit three structural gene Y-linkedInfInf
ENSMUSG00000112616Gm47434Predicted gene 47434719Inf
ENSMUSG00000025582Nptx1Neuronal pentraxin 14.7411.91
ENSMUSG00000024164C3Complement component 34.4711.59
ENSMUSG00000039457PplPeriplakin4.3011.11
ENSMUSG00000025784Clec3bC-type lectin domain family three member b3.998.60
ENSMUSG00000002944Cd36CD36 molecule3.203.45
ENSMUSG00000035385Ccl2Chemokine (C-C motif) ligand 22.862.84
ENSMUSG00000095478Gm9824Predicted pseudogene 98242.604.14
ENSMUSG00000038642CtssCathepsin S2.583.19
ENSMUSG00000043719Col6a6Collagen type VI alpha 62.444.64
ENSMUSG00000033327TnxbTenascin XB2.373.61
ENSMUSG00000069516Lyz2Lysozyme 22.303.08
ENSMUSG00000016494Cd34CD34 antigen2.292.26
ENSMUSG00000042129Rassf4Ras association (RalGDS/AF-6) domain family member 42.293.43
ENSMUSG00000004730Adgre1Adhesion G-protein-coupled receptor E12.272.49
ENSMUSG00000030144Clec4dC-type lectin domain family member d2.263.74
ENSMUSG00000029816GpnmbGlycoprotein (transmembrane) nmb2.222.66
ENSMUSG00000042286Stab1Stabilin 12.182.70
ENSMUSG00000020120PlekPleckstrin2.182.99
ENSMUSG00000040254Sema3dSema domain immunoglobulin domain (Ig) short basic domain secreted (semaphorin) 3D2.172.89
ENSMUSG00000005268PrlrProlactin receptor2.174.44
ENSMUSG00000024621Csf1rColony-stimulating factor one receptor2.102.74
ENSMUSG00000074896Ifit3Interferon-induced protein with tetratricopeptide repeats 32.043.96
ENSMUSG00000002985ApoeApolipoprotein E2.032.51
ENSMUSG00000057137Tmem140Transmembrane protein 1402.023.18
ENSMUSG00000002289Angptl4Angiopoietin-like 42.025.94
ENSMUSG00000050335Lgals3Lectin galactose binding soluble 31.992.66
ENSMUSG00000090877Hspa1bHeat-shock protein 1B1.982.13
ENSMUSG00000054404Slfn5Schlafen 51.963.77
ENSMUSG00000031209HephHephaestin1.922.48
ENSMUSG00000027996Sfrp2Secreted frizzled-related protein 21.915.68
ENSMUSG00000050953Gja1Gap junction protein alpha 11.902.45
ENSMUSG00000005413Hmox1Heme oxygenase 11.901.97
ENSMUSG00000046805Mpeg1Macrophage expressed gene 11.852.57
ENSMUSG00000022037CluClusterin1.833.06
ENSMUSG00000026389Steap3STEAP family member 31.812.24
ENSMUSG00000041577PrelpProline arginine-rich end leucine-rich repeat1.812.01
ENSMUSG00000027339Rassf2Ras association (RalGDS/AF-6) domain family member 21.802.72

These findings collectively support the potential mechanism that DYRK2 governs ciliogenesis by, at least in part, maintaining the expression of Aurka and other disassembly genes.

Discussion

DYRK2 is a positive regulator of Hh signaling

Although evidence indicates that DYRK2 plays important roles in the development of lower eukaryotes (Pellettieri et al., 2003; Pang et al., 2004; Lu and Mains, 2007), little is known regarding the functions of DYRK2 in mammalian development. In the present study, we demonstrate for the first time that DYRK2 is required for normal Hh signaling and embryogenesis in vivo. Varjosalo et al. have established a human full-length protein kinase cDNA and corresponding kinase activity-deficient mutant library, and they reported that DYRK2 functions as a negative regulator of Hh signaling via direct phosphorylation and induction of the proteasome-dependent degradation of GLIs using in vitro over-expression approaches (Varjosalo et al., 2008). In sharp contrast, our present study demonstrated using knockout approaches that endogenous protein levels of GLI2, and marginally the ratio of GLI3REP/GLI3FL, are decreased by deletion of Dyrk2 in vitro after SAG-treatment. Consistently, Dyrk2-/- embryos exhibited some typical phenotypes of inactivation of Hh signaling in vivo as indicated by abnormal responses but not the elimination of ligands. Taken together with the observed loss of Gli1 induction in Dyrk2-/- MEFs in vitro, we concluded that DYRK2 functions as a positive regulator of Hh signaling. GLI2 and GLI3, the key mediators of Hh signaling, are known to have specific and redundant functions (Mo et al., 1997). In skeletal patterning during development, Dyrk2-/- embryos exhibit phenotypes that are more similar to those of double Gli2 and Gli3 mutants than to those of each single mutant. Conversely, the deletion of other indispensable upstream Hh components such as Smo (Norman et al., 2009), Ptch1 (Svärd et al., 2006), Gpr161 (Hwang et al., 2018), and SuFu (Svärd et al., 2006) results in more severe defects that occur at earlier embryonic stages. The present data do not rule out the possibility that DYRK2 directly regulates Hh components. Despite this, given the evidence that Dyrk2-/- embryos and cells possess morphological abnormalities in primary cilia, it is clear that DYRK2 plays a pivotal role in regulating Hh signaling via the control of ciliogenesis.

Dyrk2 is a novel ciliogenesis-related gene in mice

Intriguingly, we found that DYRK2 negatively regulates ciliogenesis. In Chlamydomonas, certain mutations that cause flagella to assemble to excessive length (i.e. negatively regulator of ciliogenesis) have been identified, and these include mutations in LF1 through LF5 (Wilson et al., 2008; Tam et al., 2013). Among these, LF2, LF4, and LF5 encode protein kinases and are homologs of vertebrate CCRK, MAK/ICK/MOK, and CDKL5, respectively. In addition to these genes, GSK3β also negatively regulates cilia and flagella length (Yuan et al., 2012). Interestingly, DYRK2 belongs to the same kinase group as CCRK, MAK/ICK/MOK, CDKL5, and GSK3β (the CMGC group) (Becker and Sippl, 2011). To the best of our knowledge, however, the present study demonstrates for the first time that DYRK2 is a ciliogenesis-related gene and a negative regulator of ciliogenesis. Among these kinases, Dyrk2-/- embryos exhibit similar phenotypes to Ick-deletion mice in vivo such as skeletal defects and cilia morphology, although they do not possess a hydrocephalus defect (Moon et al., 2014). In response to Ick- or Mok-knockdown, cilia length depends on the activation of mTORC1 signaling (Bolton et al., 2007). Our previous study reported the activation of mTORC1 signaling in DYRK2-knockdown human breast cancer cells (Mimoto et al., 2017). As expected, mTORC1 signaling was slightly activated in Dyrk2-/- MEFs; however, rapamycin, an inhibitor of mTORC1, did not significantly affect cilia length in Dyrk2-/- MEFs. Thus, DYRK2 may control ciliogenesis through different mechanisms than those of other CMGC-kinases.

DYRK2 is required for ciliogenesis and the dynamic trafficking of Hedgehog components in cilia

Abnormal ciliary trafficking of Hh components causes dysfunction in Hh signaling in several types of mutant mice (He et al., 2014; Moon et al., 2014). Dyrk2-/- MEFs and embryos possessed disordered accumulation of Hh components (GLI2, GLI3, and SuFu) at cilia tips and exhibited elongation of cilia. On the other hand, SMO recruitment dependent on ligand stimulation was normally observed in Dyrk2-/- MEFs (Figure 10). Moreover, DYRK2 localizes at TZ, which acts as a selective barrier to control ciliary import and export of proteins (Gerhardt et al., 2016). Given the findings that ciliary localization and ciliary disorders were observed in Dyrk2-/- cells, DYRK2 could be involved in regulation of ciliary protein entry and exit. The functions of DYRK2 at TZ, however, remains to be elucidated.

Figure 10
Download asset Open asset
Schematic representation of DYRK2 in ciliogenesis and Hh signaling.

(Left panel) A schematic model of normal ciliogenesis and response to stimulation with Hh ligand. (Right panel) A schematic model ciliogenesis and response to stimulation with Hh ligand in Dyrk2-deletion. The morphology of primary cilia in Dyrk2-/- MEFs was elongated and often bulged at the tips. In Dyrk2-/- cells, downregulation of Aurka and other ciliary disassembly genes caused suppression of disassembly and elongation of primary cilia. Furthermore, abnormal ciliary trafficking caused accumulation of GLI2, GLI3, and SuFu in Dyrk2-/- cells. Consequently, the induction of Hh signaling is drastically suppressed by deletion of Dyrk2.

As a first step to elucidate the functions of DYRK2 in cilia, we focused on factors involved in ciliary length control using a transcriptome approach, and we identified the downregulation of genes related to ciliary resorption mechanisms for proliferation in Dyrk2-/- MEFs, such as Aurka, Plk1, Ube2c, Tpx2, Kif2c, and Cdc20. Among these, AURKA has been well-characterized as a disassembly factor, as transient knockdown by siRNA or treatment with an inhibitor of AURKA completely blocked ciliary disassembly during proliferation (Pugacheva et al., 2007; Inoko et al., 2012). In contrast to ciliary disassembly under proliferation, the function of AURKA for controlling ciliary length at steady state is unclear. In the present study, transient knockdown of Aurka under serum-starvation conditions induced elongation of cilia in a manner similar to that observed in Dyrk2-/- MEFs. These data imply that the down-regulation of Aurka is, at least in part, associated with the phenotypes observed after deletion of Dyrk2. The expression of Aurka is known to be regulated by pathways such as YAP/TAZ (Kim et al., 2015a) and AKT signaling (Plotnikova et al., 2015). The molecular mechanisms underlying DYRK2-mediated Aurka regulation and ciliary trafficking remain unclear. Further research is required to elucidate these mechanisms.

A possible relationship between DYRK2 and human ciliopathy

A number of syndromes caused by disorders involving ciliary proteins are categorized as skeletal ciliopathies, and these include short-rib thoracic dysplasia (SRTD), Jeune asphyxiating thoracic dystrophy (JATD), orofaciodigital syndrome (OFD), Ellis-van Creveld syndrome (EVC), and cranioectodermal dysplasia (CED) (Reiter and Leroux, 2017). In mice, deletion of Dyrk2 induces morphological abnormalities in primary cilia and skeletal defects in vivo. Additionally, DYRK2 is a ciliary protein that is primarily localized at the basal body and the TZ, which contains a growing number of ciliopathy proteins (Reiter et al., 2012). While the present study does not include any evidence to support the relationship between DYRK2 and human disease, our results do suggest a possibility that DYRK2 is involved in human ciliopathy, particularly in regard to skeletal disorders. Further investigations involving exome sequencing or genome-wide association studies using human patients will prove useful to clarify this issue.

Conclusion

In summary, we identified DYRK2 as a novel mammalian ciliogenesis-related gene in vivo and in vitro. Deletion of Dyrk2 induces abnormal ciliary morphology and trafficking of Hh pathway components and suppresses Hh signaling during mouse embryogenesis. The abnormal ciliogenesis in Dyrk2-/- cells is partially caused by downregulation of Aurka and other disassembly genes. These findings will allow for a more complete understanding of the molecular mechanisms underlying embryogenesis, ciliogenesis, and human ciliopathy.

Materials and methods

Key resources table
Reagent type
(species) or resource		DesignationSource or referenceIdentifiersAdditional information
Genetic reagent (M. musculus)Dyrk2-/- mouseThis paperN/AMaintained in K. Yoshida lab.
Cell line (M. musculus)Wild-type and Dyrk2-/- MEFsThis paperN/AMaintained in K. Yoshida lab.
Cell line (H. sapiens)hTERT-RPE1ATCCCat# CRL-4000 RRID:CVCL_4388
Transfected construct (M. musculus)mouse Aurka/pEGFP-C1This paperN/ASee Materials and methods subsection ‘Plasmid constructs’
Transfected construct (M. musculus)mouse Dyrk2/FN22K-Halo Tag-CMVd1-Flexi-vectorThis paperN/ASee Materials and methods subsection ‘Plasmid constructs’
Transfected construct (M. musculus)Dyrk2 targeting vectorKnockout Mouse Project RepositoryPG00105_X_1_G09, PG00105_X_1_E04See Materials and methods subsection ‘Plasmid constructs’
Recombinant DNA regentPlasmid pEGFP-C1
(empty vector)		TaKaRa BioCat# 6084–1

Recombinant DNA regentPlasmid pFN22K-Halo Tag-CMVd1-Flexi-vector (empty vector)PromegaCat# G2851
Transfected construct (M. musculus)Dyrk2 targeting vectorKnockout Mouse Project RepositoryPG00105_X_1_G09, PG00105_X_1_E04
Biological sample (Adenovirus)Adenovirus-CreYokoyama-Mashima et al., 2019 doi: 10.1016/j.canlet.2019.02.046.N/A
Biological sample (Adenovirus)Adenovirus-human DYRK2Yokoyama-Mashima et al., 2019 doi: 10.1016/j.canlet.2019.02.046.N/A
Biological sample (Adenovirus)Adenovirus-human DYRK2-K251RYokoyama-Mashima et al., 2019 doi: 10.1016/j.canlet.2019.02.046.N/A
Biological sample (Adenovirus)Adenovirus-GFPYokoyama-Mashima et al., 2019 doi: 10.1016/j.canlet.2019.02.046.N/A
AntibodyAnti-Acetylated-tubulin (Mouse monoclonal)Sigma-AldrichCat# T7451, RRID:AB_609894ICC (1:2000)
AntibodyAnti-ARL13B (Mouse monoclonal)AbcamCat# ab136648,N/AICC (1:300)
AntibodyAnti-ARL13B (Rabbit polyclonal)ProteintechCat# 17711–1-AP, RRID:AB_2060867ICC (1:400)
IHC (1:400)
AntibodyAnti-AURKA (Mouse monoclonal)BD TransductionCat# 610938, RRID:AB_398251WB (1:1000)
AntibodyAnti-DYRK2 (Rabbit polyclonal)Sigma-AldrichCat# HPA027230, RRID:AB_1847925WB (1:1000)
ICC (1:400)
AntibodyAnti-FOXA2 (Mouse monoclonal)Developmental Studies Hybridoma BankCat# 4C7, RRID:AB_528207IHC (1:8)
AntibodyAnti-CP110 (Rabbit polyclonal)ProteintechCat# 12780–1-AP, RRID:AB_10638480WB (1:1000)
AntibodyAnti-GAPDH (Mouse monoclonal)Santa Cruz BiotechnologyCat# sc-32233, RRID:AB_627679WB (1:3000)
AntibodyAnti-GFP (Chicken polyclonal IgY)Aves LabsCat# GFP-1020, RRID:AB_10000240ICC (1:500)
AntibodyAnti-GFP (Rabbit monoclonal)AbcamCat# ab183734, RRID:AB_2732027WB (1:30000)
AntibodyAnti-GLI1 (Rabbit polyclonal)Cell Signaling TechnologyCat# 2534, RRID:AB_2294745WB (1:500)
ICC (1:100)
AntibodyAnti-GLI2 (Goat polyclonal)R and D systemsCat# AF3635, RRID:AB_2111902WB (1:500)
ICC (1:50)
IHC (1:50)
AntibodyAnti-GLI3 (Goat polyclonal)R and D systemsCat# AF3690, RRID:AB_2232499WB (1:200)
ICC (1:100)
IHC (1:150)
AntibodyAnti-gamma-tubulin (Goat polyclonal)Santa Cruz BiotechnologyCat# sc-7396, RRID:AB_2211262ICC (1:3500)
AntibodyAnti-gamma-tubulin (Mouse monoclonal)Santa Cruz BiotechnologyCat# sc-17787, RRID:AB_628417ICC (1:400)
IHC (1:400)
AntibodyAnti-HaloTag (Rabbit polyclonal)PromegaCat# G9281, RRID:AB_713650ICC (1:700)
AntibodyAnti-IFT140 (Rabbit polyclonal)ProteintechCat# 17460–1-AP, RRID:AB_2295648ICC (1:100)
AntibodyAnti-IFT81 (Rabbit polyclonal)ProteintechCat# 11744–1-AP, RRID:AB_2121966ICC (1:50)
AntibodyAnti-IFT88 (Rabbit polyclonal)ProteintechCat# 13967–1-AP, RRID:AB_2121979ICC (1:100)
AntibodyAnti-KATANIN p60 (Mouse monoclonal)Santa Cruz BiotechnologyCat# sc-373814, RRID:AB_11014191WB (1:1000)
AntibodyAnti-KI67 (Rabbit monoclonal)AbcamCat# ab16667, RRID:AB_302459ICC (1:500)
AntibodyAnti-NPHP1 (Mouse monoclonal)SIGMA-AldrichCat# MABS2185,N/AICC (1:100)
AntibodyAnti-mTORC1 (Rabbit monoclonal)Cell Signaling TechnologyCat# 2972, RRID:AB_330978WB (1:1000)
AntibodyAnti-NKX2.2 (Mouse monoclonal)Developmental Studies Hybridoma BankCat# 74.5A5, RRID:AB_531794IHC (1:10)
AntibodyAnti-NKX6.1 (Mouse monoclonal)Developmental Studies Hybridoma BankCat# F55A10, RRID:AB_532378IHC (1:100)
AntibodyAnti-OLIG2 (Rabbit monoclonal)abcamCat# ab109186, RRID:AB_10861310IHC (1:500)
AntibodyAnti-PAX6 (Mouse monoclonal)Santa Cruz BiotechnologyCat# sc-81649, RRID:AB_1127044IHC (1:400)
AntibodyAnti-Phosho-S6 (Ser 235/236) (Rabbit monoclonal)Cell Signaling TechnologyCat# 2211, RRID:AB_331679WB (1:2000)
AntibodyAnti-P-4EBP1(Thr 37/46) (Rabbit monoclonal)Cell Signaling TechnologyCat# 2855, RRID:AB_560835WB (1:1500)
AntibodyAnti-SMO (Mouse monoclonal)Santa Cruz BiotechnologyCat# sc-166685, RRID:AB_2239686ICC (1:100)
AntibodyAnti-SuFu (Mouse monoclonal)Santa Cruz BiotechnologyCat# sc-137014, RRID:AB_2197315ICC (1:100)
AntibodyAnti-S6 (Rabbit monoclonal)Cell Signaling TechnologyCat# 2217, RRID:AB_331355WB (1:2000)
AntibodyAnti-4EBP1 (Rabbit monoclonal)Cell Signaling TechnologyCat# 9644, RRID:AB_2097841WB (1:3000)
Sequence-based reagentHuman DYRK2 siRNA#1BEX608481
Sequence-based reagentHuman DYRK2 siRNA#2ThermoFisher ScientificHSS112284
Sequence-based reagentMouse Dyrk2 siRNA#1ThermoFisher Scientific4390771 (s87545)
Sequence-based reagentMouse Dyrk2 siRNA#2ThermoFisher Scientific4390771 (s87546)
Sequence-based reagentMouse Aurka siRNA#1Integrated DNA Technologiesmm.Ri.Aurka.13.1
Sequence-based reagentMouse Aurka siRNA#2Integrated DNA Technologiesmm.Ri.Aurka.13.4
Sequence-based reagentMouse Cdc20 siRNAIntegrated DNA Technologiesmm.Ri.Cdc20.13.2
Sequence-based reagentMouse Kif2c siRNAIntegrated DNA Technologiesmm.Ri.Kif2c.13.3
Sequence-based reagentMouse Plk1 siRNAIntegrated DNA Technologiesmm.Ri.Plk1.13.1
Sequence-based reagentMouse Tpx2 siRNAIntegrated DNA Technologiesmm.Ri.Tpx2.13.1
Sequence-based reagentMouse Ube2c siRNAIntegrated DNA Technologiesmm.Ri.Ube2c.13.1
Sequence-based reagentNegative Control DsiRNA (siNegative)Integrated DNA Technologies51-01-14
Sequence-based reagentSilencer Select Negative Control (siControl)ThermoFisher Scientific4390843
Chemical compound, drugInSolution SAGMerck566660
Chemical compound, drugRapamycinLC LaboratoriesR-5000
Software, algorithmBZ-X800 AnalyzerKeyenceBZ-X800 Analyzer
Software, algorithmExcelMicrosoftMac2019
Software, algorithmFusionM and S InstrumentsFusion
Software, algorithmGraphPad Prism 7GraphPad Software IncMac OS X
Software, algorithmPikoReal Software 2.1ThermoFisher ScientificPikoReal Software 2.1

Generation of Dyrk2 knockout mice (Dyrk2-/-)

Request a detailed protocol

Dyrk2-/- mice were generated using the knockout-first strategy (Skarnes et al., 2011). A schematic representation of the targeted Dyrk2 allele is provided in Figure 1—figure supplement 1A. The Dyrk2 targeting vector (PG00105_X_1_G09 and PG00105_X_1_E04) was obtained from the Knockout Mouse Project Repository (Dyrk2 targeting project: 337–66440). Gene-targeting methods were performed according to standard protocols. Briefly, linearized vectors were electroporated into JM8A3.N1 embryonic stem (ES) cells. G418-resistant ES cell clones were analyzed using Southern blot analysis for the presence of the correct targeted-allele using BglII digestion and a 3’ external probe. Hybridization with the 3’ external probe detected 10.7 kb (wild-type allele) and 17.0 kb (targeted tm1a allele) BglII bands (Figure 1—figure supplement 1A). Six positive ES clones out of 240 clones were obtained. Chimeric mice were created by injection of the targeted ES cells into C57BL/6J blastocysts and were mated with C57BL/6J WT mice to establish germline-transmitted founders. Heterozygous knockout-first (Dyrk2tm1a) mice were identified using Southern blotting. An exon three knockout allele (Dyrk2tm1b) was generated by mating the Dyrk2tm1a mice the with CAG-Cre mice (Figure 1—figure supplement 1A). For genotyping and validation of knockout alleles, we performed PCR using the primers listed in Table 2.

Table 2
List of primer sets.
For genotyping
GeneSequence (5'→3')Accession number
Dyrk2 tm1b-WTForwardTGGGTCCAAATGCAAAGAAACGCCANC_000076.6
ReverseGCTTCTCGTTCCGCACCATCTTCAG
Dyrk2 tm1b-KOForwardCCTTCTCCCTCCTCCACTCTGACCCANC_000076.6
ReverseCCACACCTCCCCCTGAACCTGAAAC
For amplification of the probes for in situ hybridization or Southern blotting
GeneSequence (5'→3')Accession number
Mouse Foxf2ForwardGAGATTAACCCTCACTAAAGGGAGGTTATGGTGGCCTCGACATNM_010225.2
ReverseGAGTAATACGACTCACTATAGGGACACACACACCTCCCTTTTCA
Mouse Gli1ForwardGAGTATTTAGGTGACACTATAGAAGCAGGGAAGAGAGCAGACTGNM_010296.2
ReverseGAGTAATACGACTCACTATAGGGGCTGAGTGTTGTCCAGGTC
Mouse Ptch1ForwardGAGATTAACCCTCACTAAAGGGACATGGCCTCGGCTGGTAACNM_008957.3
ReverseGAGTAATACGACTCACTATAGGGTGTACCCATGGCCAACTTCG
Southern for Dyrk2ForwardCTTCGAATCCTTTTATCCTTCAGGCNC_000076.6
ReverseACATCATGTTCATTGGTTTTGCTCT
For cloning
GeneSequence (5'→3')Accession number
Mouse Aurka CDSForwardGGACTCAGATCTCGAGACATGGCTGTTGAGGGCGNM_011497.4
ReverseGTCGACTGCAGAATTCCTAAGATGATTTGCTGGTTG
Mouse Dyrk2 CDSForwardGTGCGCGATCGCCATGTTAACCAGGAAACCTTCGGCNM_001014390.2
ReverseCTCCGTTTAAACGCTAACGAGTTTCGGCAACAC
For real-time PCR
GeneSequence (5'→3')Accession number
Human DYRK2ForwardGGGGAGAAAACGTCAGTGAANM_006482.3
ReverseTCTGCGCCAAATTAGTCCTC
Human HPRT1ForwardGGACTAATTATGGACAGGACTGNM_000194.3
ReverseGCTCTTCAGTCTGATAAAATCTAC
Mouse AurkaForwardCACACGTACCAGGAGACTTACAGANM_011497.4
ReverseAGTCTTGAAATGAGGTCCCTGGCT
Mouse Cdc20ForwardGAGCTCAAAGGACACACAGCNM_023223.2
ReverseGCCACAACCGTAGAGTCTCA
Mouse Dyrk2ForwardCTACCACTACAGCCCACACGNM_001014390.2
ReverseTCTGTCCGTGGCTGTTGA
Mouse Foxf2ForwardAGCATGTCTTCCTACTCGTTGNM_010225.2
ReverseTCTTTCCTGTCGCACACT
Mouse Gli1ForwardGCACCACATCAACAGTGAGCNM_010296.2
ReverseGCGTCTTGAGGTTTTCAAGG
Mouse HprtForwardCTCATGGACTGATTATGGACAGGACNM_013556.2
ReverseGCAGGTCAGCAAAGAACTTATAGCC
Mouse Kif2cForwardGAGAGCAAGCTGACCCAGGNM_134471.4
ReverseCCTGGTGAGATCATGGCGATC
Mouse Plk1ForwardCCAAGCACATCAACCCAGTGNM_011121.4
ReverseTGAGGCAGGTAATAGGGAGACG
Mouse Ptch1ForwardCTCTGGAGCAGATTTCCAAGGNM_008957.3
ReverseTGCCGCAGTTCTTTTGAATG
Mouse ShhForwardGTGAAGCTGCGAGTGACCGNM_009170.3
ReverseCCTGGTCGTCAGCCGCCAGCACGC
Mouse Tpx2ForwardGCGAGGTTGTCAGGTGTGTANM_001141977.1
ReverseTTGATAAAGTCGGTGGGGGC
Mouse Ube2cForwardCTGCTAGGAGAACCCAACATCNM_026785.2
ReverseGCTGGAGACCTGCTTTGAATA

Animal care

Request a detailed protocol

Mice were housed individually in a temperature-controlled room under a 12 hr light/dark cycle. Determination of pregnancy in mice was achieved by the observation of a vaginal plug on day 0.5 of gestation. Animals were euthanized by anesthesia. The animal experiment protocol was approved by the Institutional Animal Care and Use Committee of Jikei University (No. 2017–065 and 2018–031), and the studies were performed in accordance with the Guidelines for the Proper Conduct of Animal Experiments of the Science Council of Japan.

Alcian blue and alizarin red staining

Request a detailed protocol

Euthanized wild-type and Dyrk2-/- mice at E18.5 and E16.5 were skinned, eviscerated, and fixed in 100% EtOH. For skeletal analysis, the embryos were stained with 1% Alcian Blue (Wako Pure Chemicals, Osaka, Japan) dissolved in 20% glacial acetic acid and 80% EtOH and 0.01% Alizarin Red (Sigma-Aldrich, St. Louis, MO) dissolved in 1% KOH. The excised tissues were observed using a stereo microscope (BioTools, Gunma, Japan). Ten embryos of each wild-type and Dyrk2-/- mice were analyzed.

In situ hybridization

Request a detailed protocol

In situ hybridization was performed according to a previous report (Fujiwara et al., 2007). Briefly, each digoxigenin (DIG)-labeled cRNA probe was amplified by PCR using primer sets (Table 2) and labeled using the Roche DIG RNA labeling kit (Merck, Schwalbach, Germany). Embryos at E10.5 and the heads of mice at E14.5 were fixed using MEMFA (2 mM EGTA, 1 mM MgSO4, and 3.7% formaldehyde) in 100 mM MOPS (pH 7.5) overnight at 4°C, and this was followed by immersion in 30% trehalose (Wako) in 20 mM HEPES to cryoprotect the tissues. Cryosections (7 μm thickness) from the transverse or sagittal plane were hybridized with DIG-labeled cRNA probe and were visualized with alkaline phosphatase-conjugated anti-DIG antibody (Merck) using 4-nitroblue tetrazolium chloride (NBT; Merck) and 5-bromo-4-chloro-3-indolyl phosphate (BCIP; Merck). The sections were observed under a BZ-X800 microscope (KEYENCE, Osaka, Japan).

Immunohistochemistry and hematoxylin and eosin (HE)-staining

View detailed protocol

Embryos at E10.5, E13.5, and E18.5 were fixed and sliced as described above. Depending on the antibody, the sections were antigen retrieved by an ImmunoSaver (Nisshin EM, Tokyo, Japan) for 60 min at 80°C. The sections were incubated with 10% (v/v) fetal bovine serum and 0.4% (v/v) Triton X-100 in HEPES buffer (blocking buffer). After washing, the sections were incubated with primary antibodies (Key resources table) in blocking buffer at 4°C overnight. After the immunoreaction, the sections were incubated with secondary antibodies using Cy3-, Cy5-, or FITC-conjugated AffiniPure donkey anti-goat, rabbit, and mouse IgG (Jackson ImmunoResearch, West Grove, PA). The sections were washed and incubated in VECTASHIELD Mounting Medium (Vector Laboratories, Burlingame, CA) containing 4,6′-diamidino-2-phenylindole dihydrochloride (DAPI). For HE-staining, the sections were stained using standard procedures. The sections were observed under a BZ-X800 fluorescence microscope (KEYENCE).

Scanning electron microscopy (SEM)

Request a detailed protocol

Wild-type and Dyrk2-/- embryos at E10.5 were washed with 0.1 M phosphate buffer (PB) (pH7.5) and fixed with 2% glutaraldehyde (TAAB Laboratories Equipment, Berkshire, England) in 0.1 M PB (pH 7.4) for 1 week at 4°C. The embryos were placed in tannic acid in 0.1 M PB for 2 hr at room temperature in darkness, and then immersed in 1% OsO4 solution for 2 hr at room temperature. After dehydration in graded ethanol, the samples were transferred into isoamyl acetate and dried at the critical point in liquid CO2, and this was followed by a metal coating procedure (Hitachi, Tokyo, Japan). The surfaces of tissues were then observed using scanning electron microscopy (Hitachi).

Plasmid constructs

Request a detailed protocol

Full-length cDNA fragments of mouse Dyrk2 and Aurka were amplified by PCR and cloned in frame into the pFN22K-HaloTag-CMVd1-Flexi-vector (Promega, Madison, WI) and pEGFP-C1 (TaKaRa Bio, Otsu, Japan), respectively. The nucleotide sequences of the primers used are listed in Table 2.

Cell culture and transfection

Request a detailed protocol

Primary mouse embryonic fibroblast (MEFs) were generated from wild-type and Dyrk2-/- embryos at E13.5. MEFs and immortalized human retinal pigment epithelia cells (hTERT-RPE1; Cat# CRL-4000, RRID:CVCL_4388, ATCC, Manassas, VA) were cultured in DMEM (nacalai tesque, Kyoto, Japan) with 10% FBS (biowest, Nuaille, France), 1% GultaMAX (Gibco, Gaithersburg, MD), and 1% Penicillin-streptomycin (nacalai tesque) at 37°C under 5% CO2. hTERT-RPE1 cells were authenticated by the STR profiling and negative for mycoplasma contamination. To induce ciliogenesis, cells were grown to 80–90% confluency and serum-starved (0.5% FBS) for 24 hr. For SAG-stimulation, cells were treated with 100 nM SAG (Merck) for 24 hr after serum-starvation. For rapamycin-stimulation, cells were treated with 0.5 µM rapamycin (LC Laboratories, Woburn, MA) for 24 hr after serum-starvation. Transient knockdown was achieved using the Lipofectamine RNAiMAX transfection regent (ThermoFisher Scientific, Waltham, MA) for 48 hr under serum-starvation conditions according to the manufacturer’s instructions with a final concentration of 6–20 nM siRNA (Key resources table). For over-expression of DYRK2-HaloTag, transfection was performed using X-tremeGENE9 (Merck) for hTERT-RPE1 cells according to the manufacturer’s instructions and the cells were cultured for 24 hr under serum-starvation condition for ciliogenesis. For over-expression of AURKA-EGFP or EGFP, transfection was performed using Xfect (TaKaRa Bio) for MEFs according to the manufacturer’s instructions, and the cells were cultured for 24 hr under serum-starvation condition for ciliogenesis.

Adenovirus infection

Request a detailed protocol

Adenovirus construction and infections were performed according to a previous report (Maekawa et al., 2013; Yokoyama-Mashima et al., 2019). Briefly, Flag-DYRK2 and Flag-DYRK2-K251R (Taira et al., 2010; Mimoto et al., 2013) were expressed depending upon Cre-expression. Following infection at a MOI (multiplicity of infection) of 100, MEFs were extracted for gene-expression analysis at 60 hr post-infection. MOI for MEFs was determined using an adenovirus construct for GFP-expression.

Immunoblotting

Request a detailed protocol

Tissues (the limb buds at E13.5) and MEFs were washed in twice and lysed using RIPA buffer containing several inhibitors (1 mM PMSF, 10 µg/ml Aprotinin, 1 µg/ml Leupeptin, 1 µg/ml Pepstatin A, 1 mM Na3VO4, 10 mM NaF, and 1 mM DTT). Equal amounts of protein (5 µg) were resolved on 4–15% Mini-PROTEA TGX Precast Protein Gels (BioRad, Hercules, CA). After electrophoresis, proteins were transferred to PVDF membranes (Merck). Membranes were blocked with 5% skim milk in tris-buffered saline (TBS) containing 0.05% Tween 20 (TBST) or 0.1% casein/gelatin in TBST, depending on the antibody. Primary and secondary antibodies were reacted in each blocking buffer (Key resources table). Signals were detected using a chemiluminescent regent, ImmunoStar LD (Wako). Signals were observed and band intensity was measured using a Fusion-Solo system (M and S Instruments, Tokyo, Japan).

Quantitative real-time polymerase chain reaction (qPCR)

Request a detailed protocol

Total RNAs were prepared from tissues (the limbs of E13.5, the mandibular arches of E10.5, and whole embryos at E9.5) and MEFs using the RNeasy mini kit (QIAGEN, Germantown, MD) or ISOGEN II (Nippon Gene, Tokyo, Japan), respectively. Reverse transcripts were obtained using PrimeScript Reverse Transcriptase (TaKaRa Bio) and subjected to qPCR using a PIKOREAL96 system (ThermoFisher Scientific). Reactions were performed in KAPA SYBR FAST qPCR Master Mix (NIPPON Genetics, Tokyo, Japan) that included 0.2 μM of a specific primer set for each gene (Table 2). Data were calculated by the comparative CT method (ΔCT method) to estimate the mRNA copy number relative to that of Hprt as an internal standard. The DNA sequence of the PCR product was confirmed by nucleotide sequencing (data not shown).

Immunocytochemistry

Request a detailed protocol

For immunocytochemistry, MEFs and hTERT-RPE1 cells were cultured on 8-well chamber slides (ThermoFisher Scientific) coated with Poly-D-lysin (Sigma-Aldrich). Cells were fixed and antigen retrieved depending on the antibody. The primary antibody reaction was performed at an appropriate dilution (Key resources table) in the presence of blocking buffer at 4°C overnight. After immunoreactions, cells were incubated with secondary antibodies using Cy3-, Cy5-, or FITC-conjugated AffiniPure donkey anti-goat, rabbit, and mouse IgG, and chicken IgY (Jackson ImmunoResearch). The cells were then washed and incubated with DAPI. Immunofluorescence was observed under a BZ-X800 fluorescence microscope (KEYENCE).

RNA-Seq

Request a detailed protocol

Total RNAs were prepared from MEFs cultured in the absence or presence of 100 nM SAG for 24 hr using RNeasy mini kit (QIAGEN) with DNase I treatment (QIAGEN). Materials were enriched for polyA sequences, and quantitative RNA-sequencing was performed using an Illumina HiSeq (Illumina, San Diego, CA). Cutadapt v1.9.1 was used to trim and filter reads, and clean data were aligned to the reference genome (ENSEMBLE, GRCm38.97) using the software HISAT 2 (v2.0.1). Relative gene expression was quantified and normalized in a FPKM (fragments per kilobase of transcript per million mapped reads) format.

STRING and gene ontology (GO) analysis

Request a detailed protocol

To determine the presence of interactions/partnerships among downregulated genes in Dyrk2-/- MEFs, protein-protein interaction networks were extracted from the STRING database (https://string-db.org) and drawn by STRING v11. Gene ontology (GO) analysis was also performed using STRING v11 to demonstrate the biological processes enriched in the altered genes. The resulting GO terms that possessed a false discovery rate (FDR) of less than 0.005 were considered as enriched biological processes.

Statistical analysis

Request a detailed protocol

Each experiment was confirmed by at least three independent biological replicates per condition. Data are presented as the means ± SEM. Prism seven software (GraphPad, San Diego, CA, USA) was used for statistical analyses. Means between two groups were compared using the Student’s t-test. Multiple inter-group differences were analyzed by one-way ANOVA (analysis of variance) followed by Tukey’s multiple comparison test.

Data availability

Data except for RNA-seq in this study are included in the manuscript and supporting files. Source data files have been provided: Figure 2-source data 1 Figure 2-figure supplement 1-source data 1 Figure 3-source data 1 Figure 3-source data 2 Figure 3-figure supplement 1-source data 1 Figure 3-figure supplement 2-source data 1 Figure 4-source data 1 Figure 4-figure supplement 1-source data 1 Figure 4-figure supplement 2-source data 1 Figure 4-figure supplement 3-source data 1 Figure 6-source data 1 Figure 6-figure supplement 3-source data 1 Figure 7-source data 1 Figure 8-source data 1 Figure 9-source data 1. RNA-seq data have been deposited in Dryad under accession code URL https://doi.org/10.5061/dryad.pnvx0k6j8.

The following data sets were generated
    1. Yoshida S
    2. Aoki K
    3. Fujiwara K
    4. Nakakura T
    5. Kawamura A
    6. Yamada K
    7. Ono M
    8. Yogosawa S
    9. Yoshida K
    (2020) Dryad Digital Repository
    The novel ciliogenesis regulator DYRK2 governs Hedgehog signaling during mouse embryogenesis.
    https://doi.org/10.5061/dryad.pnvx0k6j8

References

    1. Mo R
    2. Freer AM
    3. Zinyk DL
    4. Crackower MA
    5. Michaud J
    6. Heng HH
    7. Chik KW
    8. Shi XM
    9. Tsui LC
    10. Cheng SH
    11. Joyner AL
    12. Hui C
    (1997)
    Specific and redundant functions of Gli2 and Gli3 zinc finger genes in skeletal patterning and development
    Development 124:113–123.

Decision letter

  1. Lotte Pedersen
    Reviewing Editor; University of Copenhagen, Denmark
  2. Piali Sengupta
    Senior Editor; Brandeis University, United States

In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

Thank you for submitting your article "The novel ciliogenesis regulator DYRK2 governs Hedgehog signaling during mouse embryogenesis" for consideration by eLife. Your article has been reviewed by three peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by Piali Sengupta as the Senior Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

As the editors have judged that your manuscript is of interest, but as described below that additional experiments are required before it is published, we would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). First, because many researchers have temporarily lost access to the labs, we will give authors as much time as they need to submit revised manuscripts. We are also offering, if you choose, to post the manuscript to bioRxiv (if it is not already there) along with this decision letter and a formal designation that the manuscript is "in revision at eLife". Please let us know if you would like to pursue this option. (If your work is more suitable for medRxiv, you will need to post the preprint yourself, as the mechanisms for us to do so are still in development.)

Summary:

Yoshida et al. characterize the phenotype of Dyrk2 mutant mice, and show that loss of this kinase results in reduced Hh signaling both in vivo and in cells derived from the Dyrk2-/- embryos. They also show that Dyrk2-/- embryos and MEFs have ciliary defects- primarily longer cilia with abnormal tips, and defects in the trafficking of Hh components Gli2 and Gli3. Dyrk2 is postulated to localize to transition zone of cilia and regulate transcription of AurA, which the authors propose as the mechanism underlying ciliary length changes.

The data presented are robust and thorough. The authors are recognized leaders in understanding the role of Dyrk2 in cancer pathways and in DNA damage response through phosphorylation of diverse substrates including p53 and c-Jun/Myc. They now highlight a completely novel role of this kinase in embryonic development as a regulator of ciliary morphology and Hh signaling. Dyrk2 has also been postulated to act as scaffold for EDVP complex in proteolysis of substrates such as the centrosome protein CP110 and microtubule severing enzyme, Katanin. The authors now convincingly show a role of Dyrk2 as a positive regulator of Hh pathway by careful knockout studies during mouse embryogenesis in the context of craniofacial and skeletal development and Hh signaling assays in vitro. These results are in stark contrast to a previously published paper using Dyrk2 overexpression that proposed a negative regulatory role of Dyrk2 in Hh pathway through Gli2 and Gli3 degradation and direct phosphorylation of Gli2 at two residues (S385, S1011) (PMID: 18455992). Despite the nicely demonstrated broad role of this kinase in Hh signaling and late embryogenesis, the mechanism proposed for this postulated transition zone-localized protein in causing ciliary dysmorphology through AurA kinase transcription is unclear. Therefore, this work presents interesting findings and is generally well-performed and merits publication, though there are some additional experiments and/or questions to address that could improve the work considerably.

Essential revisions:

1) The authors show low Hh signaling by ISH/qRT PCR of Hh pathway targets in craniofacial region and limbs at e13.5. The later skeletal abnormalities are consistent with Hh signaling defects (although no polydactyly is seen). However, no neural tube patterning defects are seen. Considering that cilia length abnormalities are seen at E10.5 (earlier stages have not been looked at), and Gli2/3/SuFu are accumulated in MEF cilia irrespective of Smo activation, it is surprising that the Hh signaling defects are not observed in earlier stages of development. The neural tube development defects are shown to be unaffected only at the branchial level at E10.5. The authors should at least test total RNA levels of Hh pathway targets in early stage embryos and rule out dorsoventral patterning defects at earlier stages.

2) The phenotypes of the Dyrk2-/- mice as described seem to be fairly limited to bone growth and differentiation (and also neural crest-derived craniofacial structures). This certainly points to a role for Hh signaling, but could indicate that the phenotype is tissue specific. Is Dyrk2 expression tissue restricted? If so this would be very interesting since it would point to Dyrk2 being a tissue-specific regulator of cilia. Few proteins that regulate cilia in a cell type-specific manner have been identified and little is known about how such regulation is achieved. Making this link might increase the impact of the paper, if it is the case.

3) The localization of Dyrk2 in transition zone and/or centrosome should be better documented using transition zone markers and necessary controls for the antibody using ko MEFs.

4) The accumulation of Gli2/3 in resting MEF cilia (but not of Smo) is similar to PKA null MEFs (PMID: 22007132), which in contrast show high Hh signaling. Here, an alternative hypothesis regarding Dyrk2 function such as its role in affecting turnaround in ciliary tips and/or affecting axonemal architecture through its function as a kinase for Gli2 and/or EDVP complex scaffold, respectively might be considered.

5) A more thorough characterization of the ciliary defects in the Dyrk2-/- cells is desirable. Primarily, what happens to cilia frequency in Dyrk2-/- cells? If cilia frequency is not affected in these mutants, this would not detract from the work or the conclusions of the paper, but it is important to know the answer. They should also assess whether cilia frequency in cycling Dyrk2-/- MEFs is different- it seems possible loss of this kinase might increase cilia frequency when few cilia are typically present, especially given that they find that AurkA expression is reduced in the mutant cells. Again, it would just be interesting to know this either way.

6) The potential mechanism by which DYRK2 regulates ciliary length is insufficiently discussed/addressed in this study. First of all, the Introduction needs to provide a more thorough and accurate description of the literature relevant for ciliary length control and disassembly, as well as a clear description of what the differences are between steady state ciliary length control and ciliary disassembly observed e.g. during serum re-addition to starved cultures of mammalian cells. Second, the authors suggest that one potential mechanism by which DYRK2 negatively regulates ciliary length is by controlling expression of key cilia disassembly factors such as AURKA, but it is unclear why a transcriptomics approach was used in the first place. Moreover, the observed changes in the transcriptome could be a consequence rather than a cause of the long cilia phenotype seen in DYRK2 deficient cells. Therefore, a rescue experiment that shows normal ciliary length of DYRK2 mutant cells when AURKA expression is normalized must be provided if the authors want to claim that altered AURKA levels are responsible for the phenotype. DYRK2 is a kinase that the authors show is concentrated near the ciliary base; previous work implicated the EDVP complex in regulation of katanin (PMID: 19287380) and CP110 proteolysis (PMID: 28242748). CP110 is a key regulator of ciliogenesis also implicated in ciliary length control, thus an obvious question to ask is what happens to CP110 (centrosomal) levels in cells lacking DYRK2. This experiment should be fairly easy to do as good antibodies against CP110 are commercially available. Katanin levels could be analysed similarly.

7) Subsection “Dyrk2 deficiency cause suppression of Hedgehog signaling during mouse embryogenesis” and Figure 1: Some quantitative analysis is missing here. How many embryos/animals were examined?

8) Figure 3D: What is the relative expression levels of the wild type and mutant DYRK2 protein in these experiments and are the transfection efficiencies similar for both constructs? This is important to know in order to rule out that the observed difference in rescue effect of the two constructs is not simply due to different cellular expression level. Also, kinase-dead Dyrk2 does restore significant levels of Ptch1 transcript with respect to wild-type. Statistical significance for Gli1 levels is not mentioned with respect to wild-type. Dyrk2 could have kinase-independent functions as a scaffold.

9) Subsection “DYRK2 regulates ciliogenesis” and Figure 5—figure supplement 3: without quantification the data is not very meaningful, so either the data needs to be quantified or alternatively removed.

10) The manuscript contains several grammatical errors and typos that need to be corrected to enhance readability and clarity.

https://doi.org/10.7554/eLife.57381.sa1

Author response

Essential revisions:

1) The authors show low Hh signaling by ISH/qRT PCR of Hh pathway targets in craniofacial region and limbs at e13.5. The later skeletal abnormalities are consistent with Hh signaling defects (although no polydactyly is seen). However, no neural tube patterning defects are seen. Considering that cilia length abnormalities are seen at E10.5 (earlier stages have not been looked at), and Gli2/3/SuFu are accumulated in MEF cilia irrespective of Smo activation, it is surprising that the Hh signaling defects are not observed in earlier stages of development. The neural tube development defects are shown to be unaffected only at the branchial level at E10.5. The authors should at least test total RNA levels of Hh pathway targets in early stage embryos and rule out dorsoventral patterning defects at earlier stages.

As requested, we performed qPCR of Hh target genes using cDNA from whole embryo at E9.5. The results demonstrated a repression of Gli1 (p=0.077), Ptch1 (p<0.01), and Foxf2 (p<0.01) in Dyrk2-/- embryos newly prepared Figure 2—figure supplement 1B. These data clearly show the defect in Hh signaling in Dyrk2-/- mice at early stage embryos (E9.5).

To further confirm this finding, we performed in situ hybridization for Ptch1 at E10.5 newly prepared Figure 2—figure supplement 1C. The results demonstrated that Ptch1-expression was decreased in several regions such as the mandibular arch in Dyrk2-/- embryos, but remained unchanged in the neural tube. Based on these data, we concluded that Hh signaling is active state at the neural tube in Dyrk2-/- embryos.

Additionally, we speculate that these data have relation to a spatiotemporal expression-pattern of Dyrk2 in embryo we also commented below (Essential revisions comment 2).

According to the reviewer’s comment, we added newly prepared Figure 2—figure supplement 1B and Figure 2—figure supplement 1C, and their figure legends.

In addition, we added Figure 2—figure supplement 1—source data 1.

We also revised the following sentences in the revised text:

Results: subsection “Dyrk2 deficiency cause suppression of Hedgehog signaling during mouse embryogenesis”, third paragraph.

Materials and methods: subsection “In situ hybridization” and subsection “Quantitative real-time polymerase chain reaction (qPCR)”.

Table 2: We added information of a primer set for Ptch1-probe.

2) The phenotypes of the Dyrk2-/- mice as described seem to be fairly limited to bone growth and differentiation (and also neural crest-derived craniofacial structures). This certainly points to a role for Hh signaling, but could indicate that the phenotype is tissue specific. Is Dyrk2 expression tissue restricted? If so this would be very interesting since it would point to Dyrk2 being a tissue-specific regulator of cilia. Few proteins that regulate cilia in a cell type-specific manner have been identified and little is known about how such regulation is achieved. Making this link might increase the impact of the paper, if it is the case.

We appreciate your important suggestion and really agree with your comment.

We have tried to identify the localization of DYRK2 using wild-type and Dyrk2-/- embryos by immunohistochemistry and in situ hybridization. Indeed, we have performed the immunohistochemistry using almost all commercially available antibodies against DYRK2 (more than 15 antibodies). In addition, we have tried to develop original antibodies using two independent epitopes.

Although we have also verified various conditions (e.g. fixation- and antigen retrieved-conditions using cryo-, frozen-, and paraffin-sections), we could not successfully detect specific immuno-positive signals (i.e. detecting only wild-type but not Dyrk2-/- embryos). We have also performed in situ hybridization using several probes for Dyrk2; however, we could not obtain positive results.

We would thus argue that, in the future, we would like to try to show it in a separate study.

3) The localization of Dyrk2 in transition zone and/or centrosome should be better documented using transition zone markers and necessary controls for the antibody using ko MEFs.

As suggested, we performed immunocytostaining for a TZ marker, NPHP1, in hTERT-RPE1 cells transfected with DYRK2-Halo vector. The results demonstrated that DYRK2-Halo-tag-positive signals are co-localized in NPHP1-positive signals newly prepared Figure 5D.

We analyzed the cellular localization of DYRK2 using hTERT-RPE1 cells overexpressed DYRK2-Halo vector, because we could not find available anti-DYRK2 antibodies to detect endogenous DYRK2 by immunocytostaining. Therefore, we performed a control experiment for anti-Halo tag and DYRK2 antibody in hTERT-RPE1 cells transfected with “empty vector (pFN22K-Halo Tag-CMVd1-Flexi-vector)”. The results indicated that no signal was observed newly prepared Figure 5C.

Accordingly, we added newly prepared Figure 5C and D and their figure legends.

We also added the following sentences in the revised text: “No signal for anti-HaloTag (Figure 5C) or anti-DYRK2 (data not shown) was observed in hTERT-RPE1 cells transfected with empty vector (pFN22K-Halo Tag-CMVd1-Flexi-vector). Moreover, immuno-positive signals for DYRK2-HaloTag were co-localized with a TZ marker, NPHP1 (Figure 5D)”.

We added information of anti-NPHP1 antibody and pFN22K-Halo Tag-CMVd1-Flexi-vector (empty vector) in Key Resources Table.

4) The accumulation of Gli2/3 in resting MEF cilia (but not of Smo) is similar to PKA null MEFs (PMID: 22007132), which in contrast show high Hh signaling. Here, an alternative hypothesis regarding Dyrk2 function such as its role in affecting turnaround in ciliary tips and/or affecting axonemal architecture through its function as a kinase for Gli2 and/or EDVP complex scaffold, respectively might be considered.

Thank you for your important suggestion. As our response to Essential revisions comment 6, to identify DYRK2’s substrate involving in ciliogenesis, we have analyzed protein levels of CP110 and KATANIN p60, which are postulated as DYRK2’s substrates, in Dyrk2-/- MEFs. The results showed no obvious difference between wild-type and Dyrk2-/- MEFs in these proteins newly prepared Figure 6—figure supplement 4.

While we are now trying to identify novel substrates of DYRK2 for ciliogenesis, we need more time to accomplish. In this context, we would like to show it in a separate study regarding the identification of novel substrates of DYRK2 involving in ciliogenesis.

Accordingly, we added newly prepared Figure 6—figure supplement 4 and its figure legend.

We also added the following sentence in the revised text: “Moreover, a centrosome protein CP110 ,(Maddika and Chen 2009) and a microtubule severing enzyme, KATANIN p60 et al.,(Hossain 2017), have been identified as substrates of DYRK2 for proteolysis. In Dyrk2-/- MEFs, however, no obvious difference in protein levels of both CP110 and KATANIN p60 was observed (Figure 6—figure supplement 4)”.

We added information of anti-CP110 and KATANIN p60 antibodies in Key Resources Table.

5) A more thorough characterization of the ciliary defects in the Dyrk2-/- cells is desirable. Primarily, what happens to cilia frequency in Dyrk2-/- cells? If cilia frequency is not affected in these mutants, this would not detract from the work or the conclusions of the paper, but it is important to know the answer. They should also assess whether cilia frequency in cycling Dyrk2-/- MEFs is different- it seems possible loss of this kinase might increase cilia frequency when few cilia are typically present, especially given that they find that AurkA expression is reduced in the mutant cells. Again, it would just be interesting to know this either way.

According to the reviewer’s comment, we measured the proportion of ciliated cells newly prepared Figure 4—figure supplement 3A-B, and confirmed no difference between wild-type and Dyrk2-/- MEFs.

We also analyzed the proportion of ciliated cells in cell cycling wild-type and Dyrk2-/- MEFs using KI67-staining newly prepared Figure 4—figure supplement 3C. The results showed that both wild-type and Dyrk2-/- MEFs in KI67-positive cells were hardly ciliated.

We also added the following sentences in the revised text: “In contrast to the length and morphology of primary cilia, no difference was observed on the proportion of ciliated cells in wild-type and Dyrk2-/- MEFs (Figure 4—figure supplement 3A-B). Similarly, in cell-cycling (KI67-positive) wild-type and Dyrk2-/- MEFs, there was comparable in the proportion of ciliated cells (ciliated cells in KI67-positive cells is 1 per 199 and 1 per 139 cells in wild-type and Dyrk2-/- MEFs, respectively) (Figure 4—figure supplement 3C)”.

We added Figure 4—figure supplement 3—source data 1, and information of anti-KI67 and ARL13B (abcam) antibodies in Key Resources Table.

6) The potential mechanism by which DYRK2 regulates ciliary length is insufficiently discussed/addressed in this study. First of all, the Introduction needs to provide a more thorough and accurate description of the literature relevant for ciliary length control and disassembly, as well as a clear description of what the differences are between steady state ciliary length control and ciliary disassembly observed e.g. during serum re-addition to starved cultures of mammalian cells.

As indicated, we revised the third paragraph of the Introduction.

Second, the authors suggest that one potential mechanism by which DYRK2 negatively regulates ciliary length is by controlling expression of key cilia disassembly factors such as AURKA, but it is unclear why a transcriptomics approach was used in the first place. Moreover, the observed changes in the transcriptome could be a consequence rather than a cause of the long cilia phenotype seen in DYRK2 deficient cells. Therefore, a rescue experiment that shows normal ciliary length of DYRK2 mutant cells when AURKA expression is normalized must be provided if the authors want to claim that altered AURKA levels are responsible for the phenotype. DYRK2 is a kinase that the authors show is concentrated near the ciliary base; previous work implicated the EDVP complex in regulation of katanin (PMID: 19287380) and CP110 proteolysis (PMID: 28242748). CP110 is a key regulator of ciliogenesis also implicated in ciliary length control, thus an obvious question to ask is what happens to CP110 (centrosomal) levels in cells lacking DYRK2. This experiment should be fairly easy to do as good antibodies against CP110 are commercially available. Katanin levels could be analysed similarly.

First of all, we have also focused on and analyzed protein levels of CP110 and KATANIN p60, which are postulated as DYRK2’s substrates. Immuno-blotting of CP110 and KATANIN p60, however, showed no obvious difference between wild-type and Dyrk2-/- MEFs newly prepared Figure 6—figure supplement 4.

Therefore, to understand the phenotype of Dyrk2-/- cells in ciliogenesis in more detail and find novel clues, we performed transcriptome analysis.

Second, we performed a rescue experiment by over-expression of AURKA-EGFP in Dyrk2-/- MEFs newly prepared Figure 9. We observed a reduction of the cilia length in AURKA-EGFP-transfected Dyrk2-/- MEFs, but not in EGFP-transfected Dyrk2-/- MEFs. These data support that downregulated Aurka-expression is, at least in part, associated with phenotypes of Dyrk2-/- cells.

Accordingly, we revised following points,

Related to CP110 and KATANIN p60:

We added newly prepared Figure 6—figure supplement 4 and its figure legend.

We also revised the text subsection “Deletion of DYRK2 induces abnormal ciliary trafficking of Hedgehog pathway components”, last paragraph.

We added information of anti-CP110 and KATANIN p60 antibody in Key Resources Table.

Related to a rescue experiment of AURKA:

We added new data newly prepared Figure 9 and its figure legend.

In addition, we added Figure 9—source data 1.

We also revised the following sentences in the revised text:

Results: subsection “Deletion of Dyrk2 dysregulates the expression of Aurka and other cilia-disassembly genes”, end of first paragraph.

Materials and methods: subsection “Plasmid constructs”, subsection “Cell culture and transfection”, and subsection “Immunocytochemistry”.

Table 2: We added information of a primer set for mouse Aurka CDS.

We added information of expression vector (mouse Aurka/pEGFP-C1 and pEGFP-C1) anti-GFP antibodies in Key Resources Table.

7) Subsection “Dyrk2 deficiency cause suppression of Hedgehog signaling during mouse embryogenesis” and Figure 1: Some quantitative analysis is missing here. How many embryos/animals were examined?

According to the reviewer’s comment, we added the sentence: “Ten embryos of each wild-type and Dyrk2-/- mice were analyzed”.

8) Figure 3D: What is the relative expression levels of the wild type and mutant DYRK2 protein in these experiments and are the transfection efficiencies similar for both constructs? This is important to know in order to rule out that the observed difference in rescue effect of the two constructs is not simply due to different cellular expression level.

We added the immune-blotting data showing over-expression protein levels newly prepared Figure 3—figure supplement 1D and its figure legend, and confirmed that both WT and K251R were expressed with equal levels.

Additionally, to describe a method for determination of MOI, we added the following sentence “MOI for MEFs was determined using an adenovirus construct for GFP-expression” in the revised text, and information of an adenovirus for GFP-expression in Key Resources Table.

Also, kinase-dead Dyrk2 does restore significant levels of Ptch1 transcript with respect to wild-type. Statistical significance for Gli1 levels is not mentioned with respect to wild-type. Dyrk2 could have kinase-independent functions as a scaffold.

First, we added the P-value “p=0.254” in Figure 3D. As pointed out, kinase-dead DYRK2 (K251R) showed a moderate effect for expression of Gli1 and Ptch1. We consider that these data show a kinase independent function of DYRK2 (e.g. as scaffold protein, as the reviewers pointed out). Therefore, we added the following sentences “Additionally, over-expression of the K251R construct slightly increased Gli1 and Ptch1 expression in comparison with that of empty vector (Figure 3D). This kinase-independent effect might be associated with a function of DYRK2 as a scaffold protein Maddika and Chen, 2009”.

9) Subsection “DYRK2 regulates ciliogenesis” and Figure 5—figure supplement 3: without quantification the data is not very meaningful, so either the data needs to be quantified or alternatively removed.

According to the reviewer’s comment, we removed the data Original Figure 5—figure supplement 3: Stability of primary cilia in Dyrk2-/- MEFs. Accordingly, we deleted the following sentences from the revised text: “Although we confirmed the acetylated and glutamylated tubulin modifications in the axoneme that are associated with stability of microtubules ,(Janke and Bulinski 2011), both modifications remained unchanged in Dyrk2-/- MEFs cilia according to immunostaining. Additionally, destabilization of axonemal microtubules induced by exposure to 4 °C et al.,(He 2014) showed no difference in loss of acetylated tubulin modification compared to that observed in wild-type”.

We also deleted an information of anti-Glutamylated tubulin antibody from Key Resources Table.

10) The manuscript contains several grammatical errors and typos that need to be corrected to enhance readability and clarity.

As requested, we carefully checked grammatical errors and typos throughout the revised manuscript and appropriately revised.

https://doi.org/10.7554/eLife.57381.sa2

Article and author information

Author details

  1. Saishu Yoshida

    Department of Biochemistry, The Jikei University School of Medicine, Tokyo, Japan
    Contribution
    Conceptualization, Data curation, Formal analysis, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing - original draft, Project administration, Writing - review and editing
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-2574-6410

  2. Katsuhiko Aoki

    Department of Biochemistry, The Jikei University School of Medicine, Tokyo, Japan
    Contribution
    Investigation
    Competing interests
    No competing interests declared

  3. Ken Fujiwara

    Division of Histology and Cell Biology, Department of Anatomy, Jichi Medical University School of Medicine, Tochigi, Japan
    Contribution
    Investigation
    Competing interests
    No competing interests declared

  4. Takashi Nakakura

    Department of Anatomy, Graduate School of Medicine, Teikyo University, Tokyo, Japan
    Contribution
    Investigation
    Competing interests
    No competing interests declared

  5. Akira Kawamura

    Department of Biochemistry, The Jikei University School of Medicine, Tokyo, Japan
    Contribution
    Investigation
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-9914-7306

  6. Kohji Yamada

    Department of Biochemistry, The Jikei University School of Medicine, Tokyo, Japan
    Contribution
    Data curation, Visualization
    Competing interests
    No competing interests declared

  7. Masaya Ono

    Department of Clinical Proteomics, National Cancer Center Research Institute, Tokyo, Japan
    Contribution
    Methodology
    Competing interests
    No competing interests declared

  8. Satomi Yogosawa

    Department of Biochemistry, The Jikei University School of Medicine, Tokyo, Japan
    Contribution
    Investigation
    Competing interests
    No competing interests declared

  9. Kiyotsugu Yoshida

    Department of Biochemistry, The Jikei University School of Medicine, Tokyo, Japan
    Contribution
    Conceptualization, Supervision, Funding acquisition, Validation, Project administration, Writing - review and editing
    For correspondence
    kyoshida@jikei.ac.jp
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-3108-7383

Funding

Japan Society for the Promotion of Science (19K16781)

  • Saishu Yoshida

Japan Society for the Promotion of Science (17H03584)

  • Kiyotsugu Yoshida

Japan Society for the Promotion of Science (18K19484)

  • Kiyotsugu Yoshida

Japan Society for the Promotion of Science (16H06276 (AdAMS))

  • Kiyotsugu Yoshida

Takeda Science Foundation

  • Saishu Yoshida

the Jikei University Research Fund

  • Saishu Yoshida

Japan Society for the Promotion of Science (20H03519)

  • Kiyotsugu Yoshida

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Acknowledgements

We thank Dr. Yuki Kobayashi at Hiroshima University for constructive suggestions. This work was partially supported by JSPS KAKENHI (grant numbers 19K16781 to Saishu Yoshida and 17H03584, 18K19484, and 20H03519 to Kiyotsugu Yoshida), the Platform of Advanced Animal Model Support from MEXT of Japan (to Kiyotsugu Yoshida), the Jikei University Research Fund (to Saishu Yoshida), and the Takeda Science Foundation (to Saishu Yoshida).

Ethics

Animal experimentation: The animal experiment protocol was approved by the Institutional Animal Care and Use Committee of Jikei University (No. 2017-065 and 2018-031), and the studies were performed in accordance with the Guidelines for the Proper Conduct of Animal Experiments of the Science Council of Japan.

Senior Editor

  1. Piali Sengupta, Brandeis University, United States

Reviewing Editor

  1. Lotte Pedersen, University of Copenhagen, Denmark

Publication history

  1. Received: March 30, 2020
  2. Accepted: July 14, 2020
  3. Version of Record published: August 6, 2020 (version 1)

Copyright

© 2020, Yoshida et al.

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,208
    Page views
  • 284
    Downloads
  • 14
    Citations

Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Saishu Yoshida
  2. Katsuhiko Aoki
  3. Ken Fujiwara
  4. Takashi Nakakura
  5. Akira Kawamura
  6. Kohji Yamada
  7. Masaya Ono
  8. Satomi Yogosawa
  9. Kiyotsugu Yoshida
(2020)
The novel ciliogenesis regulator DYRK2 governs Hedgehog signaling during mouse embryogenesis
eLife 9:e57381.
https://doi.org/10.7554/eLife.57381

Categories and tags

Research organism

Further reading

    1. Developmental Biology

    MMP14 cleaves PTH1R in the chondrocyte-derived osteoblast lineage, curbing signaling intensity for proper bone anabolism

    Tsz Long Chu, Peikai Chen ... Kathryn Song Eng Cheah
    Research Article Updated

    Bone homeostasis is regulated by hormones such as parathyroid hormone (PTH). While PTH can stimulate osteo-progenitor expansion and bone synthesis, how the PTH-signaling intensity in progenitors is controlled is unclear. Endochondral bone osteoblasts arise from perichondrium-derived osteoprogenitors and hypertrophic chondrocytes (HC). We found, via single-cell transcriptomics, that HC-descendent cells activate membrane-type 1 metalloproteinase 14 (MMP14) and the PTH pathway as they transition to osteoblasts in neonatal and adult mice. Unlike Mmp14 global knockouts, postnatal day 10 (p10) HC lineage-specific Mmp14 null mutants (Mmp14ΔHC) produce more bone. Mechanistically, MMP14 cleaves the extracellular domain of PTH1R, dampening PTH signaling, and consistent with the implied regulatory role, in Mmp14ΔHC mutants, PTH signaling is enhanced. We found that HC-derived osteoblasts contribute ~50% of osteogenesis promoted by treatment with PTH 1–34, and this response was amplified in Mmp14ΔHC. MMP14 control of PTH signaling likely applies also to both HC- and non-HC-derived osteoblasts because their transcriptomes are highly similar. Our study identifies a novel paradigm of MMP14 activity-mediated modulation of PTH signaling in the osteoblast lineage, contributing new insights into bone metabolism with therapeutic significance for bone-wasting diseases.

    1. Biochemistry and Chemical Biology
    2. Developmental Biology

    O-GlcNAc glycosylation orchestrates fate decision and niche function of bone marrow stromal progenitors

    Zengdi Zhang, Zan Huang ... Hai-Bin Ruan
    Research Article Updated

    In mammals, interactions between the bone marrow (BM) stroma and hematopoietic progenitors contribute to bone-BM homeostasis. Perinatal bone growth and ossification provide a microenvironment for the transition to definitive hematopoiesis; however, mechanisms and interactions orchestrating the development of skeletal and hematopoietic systems remain largely unknown. Here, we establish intracellular O-linked β-N-acetylglucosamine (O-GlcNAc) modification as a posttranslational switch that dictates the differentiation fate and niche function of early BM stromal cells (BMSCs). By modifying and activating RUNX2, O-GlcNAcylation promotes osteogenic differentiation of BMSCs and stromal IL-7 expression to support lymphopoiesis. In contrast, C/EBPβ-dependent marrow adipogenesis and expression of myelopoietic stem cell factor (SCF) is inhibited by O-GlcNAcylation. Ablating O-GlcNAc transferase (OGT) in BMSCs leads to impaired bone formation, increased marrow adiposity, as well as defective B-cell lymphopoiesis and myeloid overproduction in mice. Thus, the balance of osteogenic and adipogenic differentiation of BMSCs is determined by reciprocal O-GlcNAc regulation of transcription factors, which simultaneously shapes the hematopoietic niche.

    1. Developmental Biology

    The slingshot phosphatase 2 is required for acrosome biogenesis during spermatogenesis in mice

    Ke Xu, Xianwei Su ... Hongbin Liu
    Research Article

    The acrosome is a membranous organelle positioned in the anterior portion of the sperm head and is essential for male fertility. Acrosome biogenesis requires the dynamic cytoskeletal shuttling of vesicles towards nascent acrosome which is regulated by a series of accessory proteins. However, much remains unknown about the molecular basis underlying this process. Here, we generated Ssh2 knock-out (KO) mice and HA-tagged Ssh2 knock-in (KI) mice to define the functions of Slingshot phosphatase 2 (SSH2) in spermatogenesis and demonstrated that as a regulator of actin remodeling, SSH2 is essential for acrosome biogenesis and male fertility. In Ssh2 KO males, spermatogenesis was arrested at the early spermatid stage with increased apoptotic index and the impaired acrosome biogenesis was characterized by defective transport/fusion of proacrosomal vesicles. Moreover, disorganized F-actin structures accompanied by excessive phosphorylation of COFILIN were observed in the testes of Ssh2 KO mice. Collectively, our data reveal a modulatory role for SSH2 in acrosome biogenesis through COFILIN-mediated actin remodeling and the indispensability of this phosphatase in male fertility in mice.